DE102013219920A1 - performance-enhanced hair treatment products - Google Patents

Abstract

The present invention relates to hair treatment compositions containing - in each case by weight - 0.0001 to 10 wt .-% of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu, wherein the amino group is free or protonated and the carboxy 0.0001 to 10 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl L-carnitine and in particular L-carnitine tartrate. In these compositions, L-carnitine, and / or carnitine derivatives and certain oilgopeptides enhance their positive effect on the hair and the hair follicle.

Description

The invention relates to hair treatment compositions, in particular so-called conditioners, with a combination of active ingredients for gentle and effective hair care.

Not least due to the heavy use of hair, for example by dyeing or perming, as well as by the cleaning of the hair with shampoos and by environmental pollution, the importance of care products with the longest possible effect increases. Such care products affect the natural structure and properties of the hair. Thus, for example, the wet and dry combability of the hair, the hold and the fullness of the hair can be optimized or the hair can be protected from increased splits following such treatments.

It has therefore long been customary to subject the hair to a special aftertreatment. In this case, the hair is treated with special active ingredients, for example quaternary ammonium salts or special polymers, usually in the form of a rinse. Depending on the formulation, this treatment improves the combability, the hold and the fullness of the hair and reduces the splitting rate.

The use of special oligopeptides for the care of keratinic fibers, for example, from WO2010 / 026010 A1 known. In particular, oligopeptides with the sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu are disclosed as being particularly suitable for hair care.

The use of L-carnitine and its derivatives in hair cosmetics is widely known, eg from EP 1 539 088 A1 and WO 2008/028895 A1 , Purine derivatives, especially caffeine are often and gladly used in hair treatment compositions, for example described in the EP 1 996 150 A1 ,

The use of pea extracts to stimulate hair follicles is in the FR 2 971 159 A1 also discloses its antioxidant effect is described, for example in the EP 2 588 075 A1 ,

There is still the need to provide active ingredients or combinations of active ingredients for cosmetic products with good care properties and good biodegradability. Especially in dye-containing and / or electrolyte-containing formulations, there is a need for additional nourishing active ingredients which can be easily incorporated into known formulations and are not weakened in their action due to incompatibilities with other ingredients.

It has now been found that L-carnitine, and / or certain carnitine derivatives and certain oilgopeptides enhance their positive effect on the hair and the hair follicle.

• a) 0,0001 bis 10 Gew.-% mindestens eines Oligopetids, das mindestens eine Aminosäuresequenz Glu-Glu-Glu
  
  aufweist, wobei die Amino-Gruppe frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können
• b) 0,0001 bis 10 Gew.-% mindestens einer Verbindung ausgewählt aus L-Carnitin, und/oder den Carnitinderivaten Acetyl-L-Carnitin, L-Carnitin-Fumarat, L-Carnitin-Citrat, Lauroyl-L-Carnitin und insbesondere L-Carnitin-Tartrat.

A first subject of the present invention are hair treatment compositions containing - in each case based on their weight -

• a) 0.0001 to 10 wt .-% of at least one oligopeptide containing at least one amino acid sequence Glu-Glu-Glu
  
  wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated
• b) 0.0001 to 10 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.

In this formula as well as in the formulas below, the parenthetized hydrogen atom of the amino group, as well as the parenthetical group of the acid function, means that the groups concerned may be present as such (then an oligopeptide having the relevant number of amino acids as shown (in the above) Formula 3) or that the amino acid sequence is present in an oligopeptide, which also comprises other amino acids - depending on where the other amino acid (s) is / are bound, the parenthetical components of the above formula by the / the other Replaced amino acid residue (s).

Hair treatment compositions for the purposes of the present invention are, for example, hair shampoos, hair conditioners, conditioning shampoos, hairsprays, hair conditioners, hair treatments, hair wraps, hair tonics, perming solutions, hair dye shampoos, hair dyes, hair fixatives, hair dressings, hairstyling preparations, hair lotions, mousses, hair gels , Hair waxes or their combinations. In view of the fact that men often shy away from the use of several different agents and / or several application steps, means according to the invention are preferably agents which the man applies anyway. Preferred agents according to the invention are therefore shampoos, conditioners or hair tonics.

The hair treatment compositions according to the invention contain, by weight, 0.0001 to 10% by weight of at least one oligopeptide containing at least one amino acid residue Glu-Glu-Glu, i. has at least three consecutive glutamic acids.

Oligopeptides in the context of the present application are peptide amides of acid amide-like linked condensation products of amino acids which comprise at least 3 and not more than 25 amino acids.

In hair treatment compositions which are preferred according to the invention, the oligopeptide comprises 5 to 15 amino acids, preferably 6 to 13 amino acids, particularly preferably 7 to 12 amino acids and in particular 8, 9 or 10 amino acids.

Depending on whether further amino acids are bound to the sequence Glu-Glu-Glu and depending on the nature of these amino acids, the molecular weight of the oligopeptide contained in the agents of the invention may vary. Hair treatment compositions preferred according to the invention are characterized in that the oligopeptide has a molecular weight of from 650 to 3000 Da, preferably from 750 to 2500 Da, particularly preferably from 850 to 2000 Da and in particular from 1000 to 1600 Da.

In summary, preferred hair treatment compositions according to the invention are characterized in that the oligopeptide comprises 5 to 15 amino acids, preferably 6 to 13 amino acids, more preferably 7 to 12 amino acids and especially 8, 9 or 10 amino acids and a molecular weight of 650 to 3000 Da, preferably 750 to 2500 Da, more preferably from 850 to 2000 Da and in particular from 1000 to 1600 Da. As can be seen from the preferred number of amino acids in the oligopeptides and the preferred molecular weight range, it is preferred to use oligopeptides which do not consist solely of the three glutamic acids but have further amino acids bound to this sequence. These other amino acids are preferably selected from certain amino acids, while certain other representatives are less preferred in the present invention.

Thus, it is preferred if the oligopeptides used in the agents according to the invention contain no methionine.

It is further preferred if the oligopeptides used in the agents according to the invention contain no cysteine and / or cystine.

It is further preferred if the oligopeptides used in the agents according to the invention contain no aspartic acid and / or asparagine.

It is further preferred if the oligopeptides used in the agents according to the invention contain no serine and / or threonine.

In contrast, it is preferred if the oligopeptides used in the agents according to the invention contain tyrosine.

It is further preferred if the oligopeptides used in the agents according to the invention contain leucine.

It is further preferred if the oligopeptides used in the agents according to the invention contain isoleucine.

It is further preferred if the oligopeptides used in the agents according to the invention contain arginine.

It is further preferred if the oligopeptides used in the agents according to the invention contain valine.

aufweist, wobei die Amino-Gruppe frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Particularly preferred oligopeptides or amino acid sequences contained in the preferred oligopeptides are described below:
A particularly preferred oligopeptide additionally contains tyrosine, which is preferably linked via its acid function to the Glu-Glu-Glu sequence. Hair treatment agents which are preferred according to the invention are therefore characterized in that the oligopeptide contained in them has at least one amino acid sequence Tyr-Glu-Glu-Glu

wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated.

aufweist, wobei die Amino-Gruppe frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Another particularly preferred oligopeptide additionally contains isoleucine, which is preferably linked to the Glu-Glu-Glu sequence via its amino function. Hair treatment compositions which are preferred according to the invention are therefore characterized in that the oligopeptide contained in them has at least one amino acid sequence Glu-Glu-Glu-Ile

wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated.

aufweist, wobei die Amino-Gruppe frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Oligopeptides which have both the abovementioned amino acids (tyrosine and isoleucine) are preferred according to the invention. Hair treatment agents according to the invention in which the oligopeptide contained in them is at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile are particularly preferred

wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated.

Further preferred oligopeptides additionally contain arginine, which is preferably bound to isoleucine

aufweist, wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Hair treatment composition according to one of claims 1 to 6, characterized in that the oligopeptide contained in them at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg

wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated.

aufweist, wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Still further preferred oligopeptides additionally contain valine, which is preferably bound to the arginine. Hair treatment agents which are further preferred according to the invention are therefore characterized in that the oligopeptide contained in them has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val

wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated.

aufweist, wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Still further preferred oligopeptides additionally contain leucine, which is preferably bound to the valine. Further preferred hair treatment compositions according to the invention are characterized in that the oligopeptide contained in them has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu

wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated.

aufweist, wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Particularly preferred oligopeptides additionally contain leucine, which is preferably bound to the tyrosine. Further preferred hair treatment compositions according to the invention are characterized in that the oligopeptide contained in them has at least one amino acid sequence Leu-Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu

wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated.

Very particular preference is given to compositions according to the invention containing at least two oligopeptides which satisfy the abovementioned criteria but differ from one another. For example, hair treatment agents containing at least two mutually different oligopetides A and B, both containing the amino acid sequence Glu-Glu-Glu, are preferred.

Such mutually different oligopeptides A and B correspond to each other in that they carry three consecutive Glu amino acids in their amino acid sequence, but have differences in the upstream or downstream amino acids. Preference is given to mutually different peptides with partial agreement, which may well be greater than in the above-mentioned three amino acids.

Thus, further preferred hair treatment compositions are characterized by containing at least two mutually different oligopetides A and B, both containing the amino acid sequence Glu-Glu-Glu-Ile.

Also preferred are hair treatment agents containing at least two mutually different oligopeptides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu.

Still further preferred hair treatment agents are characterized by containing at least two mutually different oligopetides A and B both containing the amino acid sequence Glu-Glu-Glu-Ile-Arg.

Even more preferred hair treatment agents contain at least two mutually different oligopetides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu-Ile.

Very particularly preferred hair treatment compositions are characterized in that they contain at least two mutually different oligopeptides A and B, both of which contain the amino acid sequence Glu-Glu-Glu-Ile-Arg.

Also most particularly preferred hair treatment agents contain at least two mutually different oligopetides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg.

Preferably, there is an even greater structural match in the oligopeptides. Thus, hair treatment compositions containing at least two distinct oligopetides A and B, both of which contain the amino acid sequence Glu-Glu-Glu-Ile-Arg-Val, are further preferred embodiments of the present invention.

Also preferred embodiments are hair treatment compositions containing at least two mutually different oligopetides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val.

Still further preferred hair treatment compositions according to the invention contain at least two mutually different oligopetides A and B, both of which contain the amino acid sequence Glu-Glu-Glu-Ile-Arg-Val-Leu.

Also, even more preferred hair treatment agents contain at least two mutually different oligopetides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu.

aufweist, wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können
und das Oligopeptid B die Aminosäuresequenz Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu

aufweist, wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können. Particularly preferred hair treatment agents are characterized by containing at least two different oligopetides A and B, wherein the oligopeptide A has the amino acid sequence Leu-Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu

wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated
and the oligopeptide B has the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu

wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated.

Very particularly preferred agents of this last-mentioned embodiment contain, based on the weight of the composition, 0.00001 to 1% by weight of oligopeptide A and 0.00001 to 1% by weight of oligopeptide B.

Further preferred agents of this last-mentioned embodiment contain, based on the weight of the composition, 0.00005 to 0.1% by weight of oligopeptide A and 0.00005 to 0.1% by weight of oligopeptide B.

Still further preferred agents of this latter embodiment contain, based on the weight of the agent, 0.0001 to 0.01% by weight of oligopeptide A and 0.0001 to 0.001% by weight of oligopeptide B.

It has been found that the use of the aforementioned oligopeptides gives the hair treatment compositions according to the invention outstanding properties. The compositions of the invention impart more resilience to the hairs treated with them, resulting in higher tensile strengths of the keratin fibers and a reduction in elasticity loss, e.g. when damaged by atmospheric agents. In particular, the particularly preferred oligopeptides also stabilize the moisture balance of the keratinic fibers, so that the combability improves and the aging process is delayed.

Another advantage of the compositions of the present invention is that the moldability and restructurability of keratinic fibers treated with them is improved.

The oligopeptides used in the context of the present invention, which satisfy the abovementioned conditions, can advantageously be obtained from keratinic materials. It is preferred according to the invention that these oligopeptides are used in high proportions, based on the total keratinic peptide content of the agents.

It is very particularly preferred that the highest possible proportion of all the keratinic peptides contained in the agent satisfy the abovementioned conditions.

Preferred hair treatment agents according to the invention are characterized in that at least 0.1% by weight, preferably at least 0.5% by weight, particularly preferably at least 1% by weight, more preferably at least 2.5% by weight, even more preferred at least 5% by weight, and in particular at least 10% by weight, of all the keratinic peptides contained in the composition have the amino acid sequence Glu-Glu-Glu.

Further preferred hair treatment compositions of the invention are characterized in that at least 0.1 wt .-%, preferably at least 0.5 wt .-%, more preferably at least 1 wt .-%, more preferably at least 2.5 wt .-%, even further preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Glu-Glu-Glu-Ile.

Still further preferred hair treatment compositions according to the invention are characterized in that at least 0.1 wt .-%, preferably at least 0.5 wt .-%, particularly preferably at least 1 wt .-%, more preferably at least 2.5 wt .-%, still more preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu.

Particularly preferred hair treatment compositions according to the invention are characterized in that at least 0.1 wt .-%, preferably at least 0.5 wt .-%, particularly preferably at least 1 wt .-%, more preferably at least 2.5 wt .-%, even further preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu-Ile.

Very particularly preferred hair treatment compositions according to the invention are characterized in that at least 0.1 wt .-%, preferably at least 0.5 wt .-%, particularly preferably at least 1 wt .-%, more preferably at least 2.5 wt .-%, still more preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg.

Still further preferred hair treatment compositions according to the invention are characterized in that at least 0.1 wt .-%, preferably at least 0.5 wt .-%, particularly preferably at least 1 wt .-%, more preferably at least 2.5 wt .-%, still more preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val.

Particularly preferred hair treatment compositions according to the invention are characterized in that at least 0.1% by weight, preferably at least 0.5% by weight, more preferably at least 1% by weight, more preferably at least 2.5% by weight, still further preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu.

The abovementioned conditions relate to the total content of the agents according to the invention to peptides which originate from keratinic materials. In addition to the oligopeptides of keratinic origin, of course, other peptides and / or protenihydrolysates can be used, for example from other native sources. For example, the additional use of wheat protein hydrolysates is preferred, see below.

The hair treatment compositions according to the invention contain as the second essential ingredient - based on their weight - 0.0001 to 10 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L Carnitine citrate, lauroyl L-carnitine and especially L-carnitine tartrate.

The compositions according to the invention may contain L-carnitine and / or an L-carnitine derivative or else a plurality of different L-carnitine derivatives.

L-carnitine or L-carnitine derivatives are contained in the agents according to the invention preferably in amounts of 0.001 to 10 wt .-%, based on the total preparation. Levels of 0.1 to 10 wt .-% are particularly preferred, amounts of 0.1 to 5 wt .-% are particularly preferred, and amounts of 1 to 3 wt .-% are very particularly preferred.

Particularly preferred hair treatment agents are characterized in that they contain 0.0005 to 7.5% by weight, preferably 0.001 to 6% by weight, more preferably 0.005 to 5% by weight, more preferably 0.01 to 4% by weight. % and in particular 0.1 to 3 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and especially L-carnitine tartrate.

• – 0,0002 bis 5 Gew.-%, vorzugsweise 0,0005 bis 2,5 Gew.-%, weiter bevorzugt 0,00075 bis 1 Gew.-%, besonders bevorzugt 0,001 bis 0,5 Gew.-%, weiter bevorzugt 0,002 bis 0,25 Gew.-% und insbesondere 0,005 bis 0,1 Gew.-% Oligopeptid(e) mit der Aminosäuresequenz Tyr-Glu-Glu-Glu-Ile-Arg-Val
  
  wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können,
• – 0,0005 bis 7,5 Gew.-%, vorzugsweise 0,001 bis 6 Gew.-%, weiter bevorzugt 0,005 bis 5 Gew.-%, weiter bevorzugt 0,01 bis 4 Gew.-% und insbesondere 0,1 bis 3 Gew.-% L-Carnitin-Tartrat.

According to the invention preferred hair treatment compositions contain - each based on their weight

• - 0.0002 to 5 wt .-%, preferably 0.0005 to 2.5 wt .-%, more preferably 0.00075 to 1 wt .-%, particularly preferably 0.001 to 0.5 wt .-%, more preferably 0.002 to 0.25 wt .-% and in particular 0.005 to 0.1 wt .-% oligopeptide (s) having the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val
  
  where the amino groups are free or protonated and the carboxy groups may be free or deprotonated,
• From 0.0005 to 7.5% by weight, preferably from 0.001 to 6% by weight, more preferably from 0.005 to 5% by weight, more preferably from 0.01 to 4% by weight and especially from 0.1 to 3 Wt% L-carnitine tartrate.

It has been found that the positive properties of the compositions according to the invention can be increased still further, in particular with regard to the positive effects on the hair roots and the inner structural strengthening of the keratin fibers, if the compositions contain purine or purine derivatives.

in der die Reste R¹, R² und R³ unabhängig voneinander ausgewählt sind aus -H, -OH, -NH₂, -SH und die Reste R⁴, R⁵ und R⁶ unabhängig voneinander ausgewählt sind aus -H, -CH₃ und -CH₂-CH₃, wobei folgende Verbindungen bevorzugt sind:

• – Purin (R¹ = R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – Adenin (R¹ = NH₂, R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – Guanin (R¹ = OH, R² = NH₂, R³ = R⁴ = R⁵ = R⁶ = H)
• – Harnsäure (R¹ = R² = R³ = OH, R⁴ = R⁵ = R⁶ = H)
• – Hypoxanthin (R¹ = OH, R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – 6-Purinthiol (R¹ = SH, R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – 6-Thioguanin (R¹ = SH, R² = NH₂, R³ = R⁴ = R⁵ = R⁶ = H)
• – Xanthin (R¹ = R² = OH, R³ = R⁴ = R⁵ = R⁶ = H)
• – Coffein (R¹ = R² = OH, R³ = H, R⁴ = R⁵ = R⁶ = CH³)
• – Theobromin (R¹ = R² = OH, R³ = R⁴ = H, R⁵ = R⁶ = H)
• – Theophyllin (R¹ = R² = OH, R³ = H, R⁴ = CH₃, R⁵ = CH₃, R⁶ = H).

Hair treatment agents preferred according to the invention are characterized in that they contain 0.0005 to 7.5% by weight, preferably 0.001 to 6% by weight, more preferably 0.005 to 5% by weight, more preferably 0.01 to 4% by weight. % and in particular 0.1 to 3 wt .-% purine and / or purine derivative (s) of the formula (I)

in which the radicals R ¹ , R ² and R ^{3 are} independently selected from -H, -OH, -NH ₂ , -SH and the radicals R ⁴ , R ⁵ and R ^{6 are} independently selected from -H, -CH ₃ and -CH ₂ -CH ₃ , where the following compounds are preferred:

• Purine (R ¹ = R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Adenine (R ¹ = NH ₂ , R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Guanine (R ¹ = OH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Uric acid (R ¹ = R ² = R ³ = OH, R ⁴ = R ⁵ = R ⁶ = H)
• Hypoxanthine (R ¹ = OH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• 6-purethiol (R ¹ = SH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• 6-thioguanine (R ¹ = SH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Xanthine (R ¹ = R ² = OH, R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Caffeine (R ¹ = R ² = OH, R ³ = H, R ⁴ = R ⁵ = R ⁶ = CH ³ )
• - Theobromine (R ¹ = R ² = OH, R ³ = R ⁴ = H, R ⁵ = R ⁶ = H)
• Theophylline (R ¹ = R ² = OH, R ³ = H, R ⁴ = CH ₃ , R ⁵ = CH ₃ , R ⁶ = H).

Preferred agents according to the invention contain purine and / or purine derivatives in narrower quantitative ranges. Here are inventively preferred cosmetic agents characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s).

Depending on the desired application of the cosmetic agent may vary the nature and amount of purine derivative. Caffeine has proved particularly useful in hair cosmetic formulations, for example in shampoos and conditioners, preferably in amounts of from 0.005 to 0.25% by weight, more preferably from 0.01 to 0.1% by weight and in particular from 0.01 to 0.05 wt .-% (in each case based on the agent) can be used.

• – 0,0002 bis 5 Gew.-%, vorzugsweise 0,0005 bis 2,5 Gew.-%, weiter bevorzugt 0,00075 bis 1 Gew.-%, besonders bevorzugt 0,001 bis 0,5 Gew.-%, weiter bevorzugt 0,002 bis 0,25 Gew.-% und insbesondere 0,005 bis 0,1 Gew.-% Oligopeptid(e) mit der Aminosäuresequenz Tyr-Glu-Glu-Glu-Ile-Arg-Val
  
  wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können,
• – 0,0005 bis 7,5 Gew.-%, vorzugsweise 0,001 bis 6 Gew.-%, weiter bevorzugt 0,005 bis 5 Gew.-%, weiter bevorzugt 0,01 bis 4 Gew.-% und insbesondere 0,1 bis 3 Gew.-% L-Carnitin-Tartrat,
• – 0,001 bis 2,5 Gew.-%, vorzugsweise 0,0025 bis 1 Gew.-%, besonders bevorzugt 0,005 bis 0,5 Gew.-% und insbesondere 0,01 bis 0,1 Gew.-% Coffein.

According to the invention preferred hair treatment compositions contain - each based on their weight

• - 0.0002 to 5 wt .-%, preferably 0.0005 to 2.5 wt .-%, more preferably 0.00075 to 1 wt .-%, particularly preferably 0.001 to 0.5 wt .-%, more preferably 0.002 to 0.25 wt .-% and in particular 0.005 to 0.1 wt .-% oligopeptide (s) having the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val
  
  where the amino groups are free or protonated and the carboxy groups may be free or deprotonated,
• From 0.0005 to 7.5% by weight, preferably from 0.001 to 6% by weight, more preferably from 0.005 to 5% by weight, more preferably from 0.01 to 4% by weight and especially from 0.1 to 3 Wt% L-carnitine tartrate,
• - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0.1 wt .-% caffeine.

The positive effects on the hair, especially with regard to wet and dry combing as well as the curl retention, can be increased even further if the compositions contain extracts of peas (Pisum sativum).

Hair treatment agents preferred according to the invention contain from 0.0005 to 7.5% by weight, preferably from 0.001 to 6% by weight, more preferably from 0.005 to 5% by weight, more preferably from 0.01 to 4% by weight and in particular 0, 1 to 3 wt .-% of at least one extract of Pisum sativium.

• – 0,0002 bis 5 Gew.-%, vorzugsweise 0,0005 bis 2,5 Gew.-%, weiter bevorzugt 0,00075 bis 1 Gew.-%, besonders bevorzugt 0,001 bis 0,5 Gew.-%, weiter bevorzugt 0,002 bis 0,25 Gew.-% und insbesondere 0,005 bis 0,1 Gew.-% Oligopeptid(e) mit der Aminosäuresequenz Tyr-Glu-Glu-Glu-Ile-Arg-Val
  
  wobei die Amino-Gruppen frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können,
• – 0,0005 bis 7,5 Gew.-%, vorzugsweise 0,001 bis 6 Gew.-%, weiter bevorzugt 0,005 bis 5 Gew.-%, weiter bevorzugt 0,01 bis 4 Gew.-% und insbesondere 0,1 bis 3 Gew.-% L-Carnitin-Tartrat,
• – 0,001 bis 2,5 Gew.-%, vorzugsweise 0,0025 bis 1 Gew.-%, besonders bevorzugt 0,005 bis 0,5 Gew.-% und insbesondere 0,01 bis 0,1 Gew.-% Coffein,
• – 0,0005 bis 7,5 Gew.-%, vorzugsweise 0,001 bis 6 Gew.-%, weiter bevorzugt 0,005 bis 5 Gew.-%, weiter bevorzugt 0,01 bis 4 Gew.-% und insbesondere 0,1 bis 3 Gew.-% mindestens eines Extraktes von Pisum sativium.

It is highly preferred that all of the above conditions be satisfied simultaneously. Particularly preferred hair treatment compositions according to the invention contain - in each case based on their weight

• - 0.0002 to 5 wt .-%, preferably 0.0005 to 2.5 wt .-%, more preferably 0.00075 to 1 wt .-%, particularly preferably 0.001 to 0.5 wt .-%, more preferably 0.002 to 0.25 wt .-% and in particular 0.005 to 0.1 wt .-% oligopeptide (s) having the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val
  
  where the amino groups are free or protonated and the carboxy groups may be free or deprotonated,
• From 0.0005 to 7.5% by weight, preferably from 0.001 to 6% by weight, more preferably from 0.005 to 5% by weight, more preferably from 0.01 to 4% by weight and especially from 0.1 to 3 Wt% L-carnitine tartrate,
• From 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0.1% by weight of caffeine,
• From 0.0005 to 7.5% by weight, preferably from 0.001 to 6% by weight, more preferably from 0.005 to 5% by weight, more preferably from 0.01 to 4% by weight and especially from 0.1 to 3 Wt .-% of at least one extract of Pisum sativium.

The agents according to the invention may contain further active ingredients and adjuvants. These are described below.

The agents according to the invention preferably additionally comprise at least one emulsifier or a surfactant, surface-active substances being referred to as surfactants or as emulsifiers, depending on the field of use, and selected from anionic, cationic, zwitterionic, ampholytic and nonionic surfactants and emulsifiers.

Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight and in particular from 5 to 25% by weight of anionic and / or nonionic (s) and / or cationic and / or amphoteric surfactant (s).

Suitable anionic surfactants and emulsifiers for the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups and hydroxyl groups may be present in the molecule. Examples of suitable anionic surfactants and emulsifiers are, in each case in the form of the sodium, potassium and ammonium as well as the mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group,

• - linear and branched fatty acids with 8 to 30 carbon atoms (soaps),
• Ether carboxylic acids of the formula RO- (CH ₂ -CH ₂ O) _x -CH ₂ -COOH, in which R is a linear alkyl group having 8 to 30 C atoms and x = 0 or 1 to 16,
• Acylsarcosides having 8 to 24 C atoms in the acyl group,
• Acyltaurides having 8 to 24 carbon atoms in the acyl group,
• Acyl isethionates having 8 to 24 C atoms in the acyl group,
• - linear alkanesulfonates having 8 to 24 carbon atoms,
• - linear alpha-olefin sulfonates having 8 to 24 carbon atoms,
• Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 C atoms,
• Acylglutamates of the formula (TI),
  
  in which R ¹ CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, which are derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as, for example, C _12/14 or C _12/18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, in particular sodium N-cocoyl and sodium N-stearoyl-L-glutamate,
• Esters of a hydroxy-substituted di- or tricarboxylic acid of the general formula (T-II),
  
  wherein X is H or a -CH ₂ COOR group, Y is H or -OH is under the condition that Y is H when X is -CH ₂ COOR, R, R ¹ and R ^{2 are} independently a hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C ₆ -C ₁₈ ) -alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C ₆ -C ₁₆ ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R, R ¹ or R ^{2 is} a radical Z,
• Esters of sulfosuccinic acid or sulfosuccinates of general formula (T-III),
  
  in which M ^{(n + / n)} for n = 1 represents a hydrogen atom, an alkali metal cation, an ammonium group or the cation of an ammonium organic base and for n = 2 an alkaline earth metal cation and R ¹ and R ² independently of one another represent a hydrogen atom, an alkali metal cation or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group consisting of etherified (C ₆ -C ₁₈ ) -alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C ₆ -C ₁₆ ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R ¹ or R ^{2 is} a radical Z,
• Sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 24 C atoms in the alkyl group and 1 to 6 oxyethyl groups,
• Alkyl sulfates and alkyl polyglycol ether sulfates of the formula R- (O-CH ₂ -CH ₂ ) _x -OSO ₃ H, in which R is a preferably linear alkyl group having 8 to 30 C atoms and x = 0 or 1-12,
• Esters of tartaric acid and citric acid with alcohols which are adducts of about 2-15 molecules of ethylene oxide and / or propylene oxide with C _8-22 fatty alcohols,
• Alkyl and / or alkenyl ether phosphates,
• - sulfated fatty acid alkylene glycol esters,
• Monoglyceride sulfates and monoglyceride ether sulfates.

Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which in particularly preferred embodiments of an octanoyl, decanoyl, lauroyl , Myristoyl, palmitoyl and stearoyl radical, esters of tartaric acid, citric acid or succinic acid or of the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium coco Glucoside sulfosuccinates, Alkylpolyglycolethersulfate and ether carboxylic acids having 8 to 18 carbon atoms in the alkyl group and up to 12 ethoxy groups in the molecule, sulfosuccinic acid mono- and dialkyl ester having 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethylester having 8 to 18 carbon atoms in the Alkyl group and 1 to 6 ethoxy groups. Zwitterionic surfactants and emulsifiers are those surface-active compounds which carry at least one quaternary ammonium group and at least one -COO ^(-) or -SO ₃ ^(-) group in the molecule. Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl 3-hydroxyethylimidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and cocoacylaminoethylhydroxyethylcarboxymethylglycinate. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Ampholytic surfactants and emulsifiers are understood to mean those surface-active compounds which, apart from a C ₈ -C ₂₄ -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SO ₃ H group and are capable of forming internal salts , Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C Atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C ₁₂ -C ₁₈ acylsarcosine.

• – Anlagerungsprodukte von 2 bis 50 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare und verzweigte Fettalkohole mit 8 bis 30 C-Atomen, an Fettsäuren mit 8 bis 30 C-Atomen und an Alkylphenole mit 8 bis 15 C-Atomen in der Alkylgruppe,
• – C₁₂-C₃₀-Fettsäuremono- und -diester von Anlagerungsprodukten von 1 bis 30 Mol Ethylenoxid an Polyole mit 3 bis 6 Kohlenstoffatomen, insbesondere an Glycerin,
• – Anlagerungsprodukte von 5 bis 60 Mol Ethylenoxid an Rizinusöl und gehärtetes Rizinusöl,
• – Polyolfettsäure(partial)ester, wie Hydagen^® HSP (Cognis) oder Sovermol^®-Typen (Cognis), insbesondere von gesättigten C_8-30-Fettsäuren,
• – alkoxylierte Triglyceride,
• – alkoxylierte Fettsäurealkylester,
• – Aminoxide,
• – Fettsäurealkanolamide, Fettsäure-N-alkylglucamide und Fettamine sowie deren Ethylenoxid- oder Polyglycerin-Anlagerungsprodukte,
• – Sorbitanfettsäureester und Anlagerungsprodukte von Ethylenoxid an Sorbitanfettsäureester wie beispielsweise die Polysorbate,
• – Zuckerfettsäureester und Methylglucosid-Fettsäureester sowie deren Ethylenoxid- oder Polyglycerin-Anlagerungsprodukte,
• – Alkylpolyglycoside entsprechend der allgemeinen Formel RO-(Z)_x wobei R für Alkyl, Z für Zucker sowie x für die Anzahl der Zuckereinheiten steht.

Nonionic surfactants and emulsifiers contain as hydrophilic group z. A polyol group, a polyalkylene glycol ether group or a combination of polyol and polyglycol ether groups. Such compounds are, for example

• - Addition products of 2 to 50 moles of ethylene oxide and / or 0 to 5 moles of propylene oxide to linear and branched fatty alcohols having 8 to 30 carbon atoms, to fatty acids having 8 to 30 carbon atoms and to alkylphenols having 8 to 15 carbon atoms in the alkyl group,
• C ₁₂ -C ₃₀ -fatty acid mono- and diesters of addition products of from 1 to 30 mol of ethylene oxide onto polyols having from 3 to 6 carbon atoms, in particular to glycerol,
• Adducts of 5 to 60 moles of ethylene oxide with castor oil and hydrogenated castor oil,
• - polyol fatty (partial) ester as Hydagen ^® HSP (Cognis) or Sovermol ^® grades (Cognis), especially of saturated C _8-30 fatty acids,
• - alkoxylated triglycerides,
• - alkoxylated fatty acid alkyl esters,
• - amine oxides,
• Fatty acid alkanolamides, fatty acid N-alkylglucamides and fatty amines and their ethylene oxide or polyglycerol addition products,
• Sorbitan fatty acid esters and adducts of ethylene oxide with sorbitan fatty acid esters such as the polysorbates,
• Sugar fatty acid esters and methyl glucoside fatty acid esters and their ethylene oxide or polyglycerol addition products,
• - Alkylpolyglycoside according to the general formula RO- (Z) _x wherein R is alkyl, Z is sugar and x is the number of sugar units.

• – im wesentlichen aus C₈- und C₁₀-Alkylgruppen,
• – im wesentlichen aus C₁₂- und C₁₄-Alkylgruppen,
• – im wesentlichen aus C₈- bis C₁₆-Alkylgruppen oder
• – im wesentlichen aus C₁₂- bis C₁₆-Alkylgruppen oder
• – im wesentlichen aus C₁₆ bis C₁₈-Alkylgruppen besteht.

Particular preference is given to those alkylpolyglycosides in which R

• Consisting essentially of C ₈ and C ₁₀ -alkyl groups,
• Essentially of C ₁₂ and C ₁₄ alkyl groups,
• - Essentially from C ₈ - to C ₁₆ alkyl groups or
• - Essentially from C ₁₂ - to C ₁₆ alkyl groups or
• - Consists essentially of C ₁₆ to C ₁₈ alkyl groups.

As sugar building block Z it is possible to use any desired mono- or oligosaccharides. Usually, sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used. Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose. Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.

• – Gemische aus Alkyl-(oligo)-glucosiden und Fettalkoholen, z. B. Montanov^®68,
• – Sterine, z. B. Ergosterin, Stigmasterin, Sitosterin und Mykosterine,
• – Phospholipide, z. B. Lecithine bzw. Phosphatidylcholine,
• – Polyglycerine und Polyglycerinderivate wie beispielsweise Polyglycerinpoly-12-hydroxystearat (Dehymuls^® PGPH) oder Triglycerindiisostearat (Lameform^® TGI),
• – alkoxylierte Polydialkylsiloxane (INCI-Bezeichnung: Dimethicone Copolyol).

The alkylpolyglycosides which can be used according to the invention contain on average from 1.1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1.1 to 1.8.

• - Mixtures of alkyl (oligo) glucosides and fatty alcohols, eg. B. Montanov ^® 68,
• - sterols, e.g. Ergosterol, stigmasterol, sitosterol and mycosterols,
• - Phospholipids, z. B. lecithins or phosphatidylcholines,
• - polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate (Dehymuls ^® PGPH) or Triglycerindiisostearat (Lameform ^® TGI),
• - alkoxylated polydialkylsiloxanes (INCI name: Dimethicone Copolyol).

The preferred nonionic surface-active substances have been the alkylpolyglycosides, optionally mixed with fatty alcohols, alkoxylated polydialkylsiloxanes, alkylene oxide addition products of saturated linear fatty alcohols and fatty acids with 2 to 30 moles of ethylene oxide per mole of fatty alcohol or fatty acid.

Also usable according to the invention are cationic surfactants of the quaternary ammonium compound type, the esterquats and the amidoamines. Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides. The long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as. In cetyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, lauryl dimethyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride and tricetylmethyl ammonium chloride. Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.

Very particular preference is given to compositions according to the invention which additionally contain fatty alcohol (s) and / or fatty alcohol alkoxylate (s), preferably C _12-22 fatty alcohol (s) and / or C _12-22 fatty alcohol ethoxylate (s) with 10 to 30 EO units , Particularly preferably C _16-18 fatty alcohol (s) and / or C _16-18 fatty alcohol ethoxylate (s) having 12 to 20 EO units, preferably in amounts of 5 to 20 wt .-%, preferably from 7.5 to 17.5 wt .-% and in particular from 10 to 15 wt .-%, each based on the weight of the composition.

In summary, hair-treatment compositions according to the invention are preferred which, based on their weight, contain from 0.1 to 20% by weight, preferably from 0.25 to 17.5% by weight and in particular from 5 to% by weight of anionic surfactant (s ), particularly preferred fatty alcohol ether sulfates of the formula H ₃ C- (CH ₂ ) _n - (OCH ₂ CH ₂ ) _k -OSO ₃ ^- M ⁺ in which n represents values of from 5 to 21, preferably from 7 to 19, more preferably from 9 to 17 and in particular from 11 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8 , 9 or 10, preferably 1, 2 or 3 and especially 2, and M is a cation from the group Na ⁺ , K ⁺ NH ⁺ ₄ , ½ Mg ²⁺ , ½ Zn ²⁺ , preferably Na ⁺ , stand.

• – N-Alkylglycine,
• – N-Alkylpropionsäuren,
• – N-Alkylaminobuttersäuren,
• – N-Alkyliminodipropionsäuren,
• – N-Hydroxyethyl-N-alkylamidopropylglycine,
• – N-Alkyltaurine,
• – N-Alkylsarcosine,
• – 2-Alkylaminopropionsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe,
• – Alkylaminoessigsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe,
• – N-Kokosalkylaminopropionat,
• – Kokosacylaminoethylaminopropionat
• – C₁₂-C₁₈-Acylsarcosin,
• – N-Alkyl-N,N-dimethylammonium-glycinate, beispielsweise Kokosalkyl-dimethylammoniumglycinat,
• – N-Acyl-aminopropyl-N,N-dimethylammoniumglycinate, beispielsweise Kokosacylaminopropyl-dimethylammoniumglycinat,
• – 2-Alkyl-3-carboxymethyl-3-hydroxyethyl-imidazoline mit jeweils 8 bis 18 C-Atomen in der Alkyl- oder Acylgruppe
• – Kokosacylaminoethylhydroxyethylcarboxymethylglycinat
• – der unter der INCI-Bezeichnung Cocamidopropyl Betain bekannten Verbindungen,
• – der unter der INCI-Bezeichnung Disodium Cocoamphodiacetate bekannten Verbindungen,

enthalten, wobei bevorzugte Mittel das bzw. die amphotere(n) Tensid(e) in Mengen von 1 bis 15 Gew.-%, vorzugsweise von 2,5 bis 12 Gew.-% und insbesondere von 5 bis 10 Gew.-%, jeweils bezogen auf das gesamte Mittel, enthalten. Preferred hair treatment compositions according to the invention are further characterized in that they additionally contain amphoteric surfactant (s), preferably from the groups of

• - N-alkylglycines,
• N-alkylpropionic acids,
• N-alkylaminobutyric acids,
• N-alkyliminodipropionic acids,
• N-hydroxyethyl-N-alkylamidopropylglycines,
• N-alkyl taurines,
• N-alkyl sarcosines,
• 2-alkylaminopropionic acids each having about 8 to 24 C atoms in the alkyl group,
• Alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group,
• N-cocoalkylaminopropionate,
• - cocoacylaminoethylaminopropionate
• C ₁₂ -C ₁₈ acyl sarcosine,
• N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate,
• N-acyl-aminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyl-dimethylammonium glycinate,
• - 2-Alkyl-3-carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group
• Cocoacylaminoethylhydroxyethylcarboxymethylglycinate
• The compounds known by the INCI name cocamidopropyl betaine,
• The compounds known under the INCI name Disodium Cocoamphodiacetate,

preferred agents containing the amphoteric surfactant (s) in amounts of 1 to 15 wt .-%, preferably from 2.5 to 12 wt .-% and in particular from 5 to 10 wt .-%, in each case based on the total agent included.

As a further optional constituent, the agents according to the invention may contain from 0.01 to 10% by weight of at least one polymer from the group of cationic and / or amphoteric polymers.

Cationic or amphoteric polymers are to be understood as meaning polymers which have a group in the main and / or side chain which may be "temporary" or "permanent" cationic. According to the invention, "permanently cationic" refers to those polymers which have a cationic group, irrespective of the pH of the agent. These are usually polymers containing a quaternary nitrogen atom, for example in the form of an ammonium group. Preferred cationic groups are quaternary ammonium groups. In particular, those polymers in which the quaternary ammonium group is bonded via a C 1-4 hydrocarbon group to a polymer main chain constructed from acrylic acid, methacrylic acid or derivatives thereof have proven to be particularly suitable.

In addition to cationic polymers or in their place, the agents according to the invention can also contain amphoteric polymers. These additionally have at least one negatively charged group in the molecule and are also referred to as zwitterionic polymers.

Preferably, the polymer or polymers are used within narrower ranges. Thus, agents according to the invention are preferred which, based on their weight, are from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight, more preferably from 0.2 to 3.5% by weight and in particular from 0.25 to 2.5% by weight of amphoteric polymer (s).

Regardless of whether the agents contain amphoteric polymers or not, further preferred agents according to the invention are characterized in that they contain, based on their weight, from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight. -%, particularly preferably 0.2 to 3.5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) polymer (s) included. Cationic polymers which can preferably be used according to the invention are described below:

in der R¹= -H oder -CH₃ ist, R², R³ und R⁴ unabhängig voneinander ausgewählt sind aus C1-4-Alkyl-, -Alkenyl- oder -Hydroxyalkylgruppen, m = 1, 2, 3 oder 4, n eine natürliche Zahl und X^– ein physiologisch verträgliches organisches oder anorganisches Anion ist, sowie Copolymere, bestehend im wesentlichen aus den in Formel (G1-I) aufgeführten Monomereinheiten sowie nichtionogenen Monomereinheiten, sind besonders bevorzugte kationische Polymere. Im Rahmen dieser Polymere sind diejenigen erfindungsgemäß bevorzugt, für die mindestens eine der folgenden Bedingungen gilt:

• – R¹ steht für eine Methylgruppe
• – R², R³ und R⁴ stehen für Methylgruppen
• – m hat den Wert 2.

Homopolymers of the general formula (G1-I),

in which R ¹ = -H or -CH ₃ , R ² , R ³ and R ^{4 are} independently selected from C 1-4 -alkyl, -alkenyl or -hydroxyalkyl groups, m = 1, 2, 3 or 4, n is a natural number and X ^{- is} a physiologically acceptable organic or inorganic anion, as well as copolymers consisting essentially of the monomer units listed in formula (G1-I) and nonionic monomer units, are particularly preferred cationic polymers. In the context of these polymers, preference is given to those according to the invention for which at least one of the following conditions applies:

• - R ¹ is a methyl group
• - R ² , R ³ and R ⁴ are methyl groups
• - m has the value 2.

Suitable physiologically tolerated counterions X ^- include, for example, halide ions, sulfate ions, phosphate ions, methosulfate ions and organic ions such as lactate, citrate, tartrate and acetate ions. Preference is given to halide ions, in particular chloride.

A particularly suitable homopolymer is, if desired, crosslinked, poly (methacryloyloxyethyltrimethylammonium chloride) with the INCI name Polyquaternium-37. Such products are available, for example under the names Rheocare ^® CTH (Cosmetic Rheologies) and Synthalen® ^® CR (Ethnichem) in trade. If desired, the crosslinking can be carried out with the aid of poly olefinically unsaturated compounds, for example divinylbenzene, tetraallyloxyethane, methylenebisacrylamide, diallyl ether, polyallylpolyglyceryl ethers, or allyl ethers of sugars or sugar derivatives such as erythritol, pentaerythritol, arabitol, mannitol, sorbitol, sucrose or glucose. Methylenebisacrylamide is a preferred crosslinking agent.

The homopolymer is preferably used in the form of a nonaqueous polymer dispersion which should not have a polymer content of less than 30% by weight. Such polymer dispersions are (under the names Salcare ^® SC 95 about 50% polymer content, additional components:
Mineral oil (INCI name: Mineral Oil) and tridecyl-polyoxypropylene-polyoxyethylene-ether (INCI name: PPG-1 trideceth-6)) and Salcare ^® SC 96 (about 50% polymer content, additional components: a mixture of diesters of Propylene glycol with a mixture of caprylic and capric acid (INCI name: Propylene Glycol Dicaprylate / Dicaprate) and Tridecylpolyoxypropylen polyoxyethylene ether (INCI name: PPG-1-Trideceth-6)) commercially available.

Copolymers having monomer units of the formula (G1-I) contain as nonionic monomer units preferably acrylamide, methacrylamide, acrylic acid-C _1-4 -alkyl esters and methacrylic acid-C _1-4 -alkyl esters. Among these nonionic monomers, the acrylamide is particularly preferred. These copolymers can also be crosslinked, as described above in the case of the homopolymers. A copolymer preferred according to the invention is the crosslinked acrylamide-methacryloyloxyethyltrimethylammonium chloride copolymer. Such copolymers in which the monomers are present in a weight ratio of about 20:80, are commercially available as approximately 50% non-aqueous polymer dispersion 92 under the name Salcare ^® SC.

• – quaternisierte Cellulose-Derivate, wie sie unter den Bezeichnungen Celquat^® und Polymer JR^® im Handel erhältlich sind. Die Verbindungen Celquat^® H 100, Celquat^® L 200 und Polymer JR^®400 sind bevorzugte quaternierte Cellulose-Derivate,
• – kationische Alkylpolyglycoside gemäß der DE-PS 44 13 686 ,
• – kationisierter Honig, beispielsweise das Handelsprodukt Honeyquat^® 50,
• – kationische Guar-Derivate, wie insbesondere die unter den Handelsnamen Cosmedia^®Guar und Jaguar^® vertriebenen Produkte,
• – polymere Dimethyldiallylammoniumsalze und deren Copolymere mit Estern und Amiden von Acrylsäure und Methacrylsäure. Die unter den Bezeichnungen Merquat^®100 (Poly(dimethyldiallylammoniumchlorid)) und Merquat^®550 (Dimethyldiallylammoniumchlorid-Acrylamid-Copolymer) im Handel erhältlichen Produkte sind Beispiele für solche kationischen Polymere,
• – Copolymere des Vinylpyrrolidons mit quaternierten Derivaten des Dialkylaminoalkylacrylats und -methacrylats, wie beispielsweise mit Diethylsulfat quaternierte Vinylpyrrolidon-Dimethylaminoethylmethacrylat-Copolymere. Solche Verbindungen sind unter den Bezeichnungen Gafquat^®734 und Gafquat^®755 im Handel erhältlich,
• – Vinylpyrrolidon-Vinylimidazoliummethochlorid-Copolymere, wie sie unter den Bezeichnungen Luviquat^® FC 370, FC 550, FC 905 und HM 552 angeboten werden,
• – quaternierter Polyvinylalkohol,
• – sowie die unter den Bezeichnungen Polyquaternium 2, Polyquaternium 17, Polyquaternium 18 und Polyquaternium 27 bekannten Polymeren mit quartären Stickstoffatomen in der Polymerhauptkette.

Further preferred cationic polymers are, for example

• - Quaternized cellulose derivatives, such as those under the names Celquat ^® and Polymer JR ^® commercially available. The compounds Celquat ^® H 100, Celquat L 200 and Polymer JR ^{® ®} 400 are preferred quaternized cellulose derivatives
• Cationic alkyl polyglycosides according to DE-PS 44 13 686 .
• - cationized honey, for example the commercial product Honeyquat ^® 50,
• - cationic guar derivatives, such as in particular the products sold under the trade names Cosmedia® ^® Guar and Jaguar ^®,
• - Dimethyldiallylammoniumsalze polymeric and their copolymers with esters and amides of acrylic acid and methacrylic acid. Under the names Merquat ^® 100 (Poly (dimethyldiallylammonium chloride)) and Merquat ^® 550 (dimethyldiallylammonium chloride-acrylamide copolymer) are examples of such cationic polymers,
• - Copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acrylate and methacrylate, such as diethyl sulfate quaternized vinylpyrrolidone-dimethylaminoethyl methacrylate copolymers. Such compounds are sold under the names Gafquat ^® 734 and Gafquat ^® 755 commercially,
• - vinylpyrrolidone vinylimidazoliummethochloride copolymers, such as those offered under the names Luviquat.RTM ^® FC 370, FC 550, FC 905 and HM 552,
• - quaternized polyvinyl alcohol,
• - as well as the polymers known under the names Polyquaternium 2, Polyquaternium 17, Polyquaternium 18 and Polyquaternium 27 with quaternary nitrogen atoms in the polymer main chain.

Can be used as cationic polymers are sold under the names Polyquaternium-24 (commercial product z. B. Quatrisoft ^® LM 200), known polymers. , Gaffix ^® VC 713 (manufactured by ISP): Also according to the invention can be used the copolymers of vinylpyrrolidone, such as the commercial products Copolymer 845 (ISP manufacturer) are Gafquat ^® ASCP 1011, Gafquat ^® HS 110, Luviquat ^® 8155 and Luviquat ^® MS 370 available are.

Cationic protein hydrolysates may also be used as cationic polymers, preferred agents being one or more cationic protein hydrolyzates from the group Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl, Hydroxypropyltrimonium Gelatin, Hydroxypropyltrimonium Hydrolyzed Casein, Hydroxypropyltrimonium Hydrolyzed Collagen, Hydroxypropyltrimonium Hydrolyzed Conchiolin Protein, Hydroxypropyltrimonium Hydrolyzed Keratin, Hydroxypropyltrimonium Hydrolyzed Rice Bran Protein, Hydroxypropyltrimonium Hydrolyzed Soy Protein, Hydroxypropyl Hydrolyzed Vegetable Protein, Hydroxypropyltrimonium Hydrolyzed Wheat Protein, Hydroxypropyltrimonium Hydrolyzed Wheat Protein / Siloxysilicate, Laurdimonium Hydroxypropyl Hydrolyzed Soy Protein, Laurdimonium Hydroxypropyl Hydrolyzed Wheat Protein, Lauridimonium Hydroxypropyl Hydrolyzed Wheat Protein / Siloxysilicate, Lauryldimonium Hydroxypropyl Hydrolyzed Casein, Lauryldimonium Hydroxypropyl Hydrolyzed Collagen, Lauryldimonium Hydroxypropyl Hydrolyzed Keratin, Lauryldimonium Hydroxypropyl Hydrolyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Casein, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Keratin, Steardimonium Hydroxypropyl Hydrolyzed Rice Protein, Steardimonium Hydroxypropyl Hydro Lyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Vegetable Protein, Steardimonium Hydroxypropyl Hydrolyzed Wheat Protein, Steartrimonium Hydroxyethyl Hydrolyzed Collagen, Quaternium-76 Hydrolyzed Collagen, Quaternium-79 Hydrolyzed Collagen, Quaternium-79 Hydrolyzed Keratin, Quaternium-79 Hydrolyzed Milk Protein, Quaternium-79 Hydrolyzed Soy Protein, Quaternium-79 Hydrolyzed Wheat Protein included.

• – Poly(methacryloyloxyethyltrimethylammoniumchlorid) (INCI: Polyquaternium-37) und/oder;
• – quaternisierten Cellulose-Derivaten (INCI: Polyquaternium 10) und/oder
• – kationischen Alkylpolyglycosiden und/oder
• – kationisertem Honig und/oder
• – kationischen Guar-Derivaten und/oder
• – polymeren Dimethyldiallylammoniumsalzen und deren Copolymeren mit Estern und Amiden von Acrylsäure und Methacrylsäure und/oder
• – Copolymeren des Vinylpyrrolidons mit quaternierten Derivaten des Dialkylaminoalkylacrylats und -methacrylats und/oder
• – Vinylpyrrolidon-Vinylimidazoliummethochlorid-Copolymeren und/oder
• – quaterniertem Polyvinylalkohol und/oder
• – Polyquaternium 2 und/oder
• – Polyquaternium-7 und/oder
• – Polyquaternium 17 und/oder
• – Polyquaternium 18 und/oder
• – Polyquaternium 24 und/oder
• – Polyquaternium 27.

In summary, hair treatment compositions according to the invention are preferred which, based on their weight, are from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight, more preferably from 0.2 to 3.5% by weight, and in particular from 0.25 to 2.5% by weight of cationic polymer (s), preferred cationic polymer (s) being / are selected from

• Poly (methacryloyloxyethyltrimethylammonium chloride) (INCI: Polyquaternium-37) and / or;
• - quaternized cellulose derivatives (INCI: Polyquaternium 10) and / or
• Cationic alkylpolyglycosides and / or
• - cationised honey and / or
• Cationic guar derivatives and / or
• Polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or
• - Copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acrylate and methacrylate and / or
• - Vinylpyrrolidone-Vinylimidazoliummethochlorid copolymers and / or
• Quaternized polyvinyl alcohol and / or
• Polyquaternium 2 and / or
• Polyquaternium-7 and / or
• - Polyquaternium 17 and / or
• - Polyquaternium 18 and / or
• - Polyquaternium 24 and / or
• - Polyquaternium 27.

• A) Monomeren mit quartären Ammoniumgruppen der allgemeinen Formel (Z-I), R¹-CH=CR²-CO-Z-(C_nH_2n)-N⁽⁺⁾R³R⁴R⁵A^(–) (Z-I) In der R¹ und R² unabhängig voneinander stehen für Wasserstoff oder eine Methylgruppe und R³, R⁴ und R⁵ unabhängig voneinander für Alkylgruppen mit 1 bis 4 Kohlenstoff-Atomen, Z eine NH-Gruppe oder ein Sauerstoffatom, n eine ganze Zahl von 2 bis 5 und A^(–) das Anion einer organischen oder anorganischen Säure ist und
• B) monomeren Carbonsäuren der allgemeinen Formel (Z-II), R⁶-CH=CR⁷-COOH (Z-II) in denen R⁶ und R⁷ unabhängig voneinander Wasserstoff oder Methylgruppen sind.

In addition to the cationic polymers or in their place, the agents of the invention may contain amphoteric polymers. In the context of the present invention preferably usable amphoteric polymers are composed essentially together

• A) monomers having quaternary ammonium groups of the general formula (ZI), R ¹ -CH = CR ² -CO-Z- (C _n H _2n ) -N ⁽⁺⁾ R ³ R ⁴ R ⁵ A ^(-) (ZI) In the R ¹ and R ² independently of one another are hydrogen or a methyl group and R ³ , R ⁴ and R ^{5 are} independently alkyl groups having 1 to 4 carbon atoms, Z is an NH group or an oxygen atom, n is an integer of 2 to 5 and A ^{(-) is} the anion of an organic or inorganic acid and
• B) monomeric carboxylic acids of the general formula (Z-II), R ⁶ -CH = CR ⁷ -COOH (Z-II) in which R ⁶ and R ^{7 are} independently hydrogen or methyl groups.

Suitable starting monomers are, for. Dimethylaminoethylacrylamide, dimethylaminoethylmethacrylamide, dimethylaminopropylacrylamide, dimethylaminopropylmethacrylamide and diethylaminoethylacrylamide when Z represents an NH group or dimethylaminoethyl acrylate, dimethylaminoethyl methacrylate and diethylaminoethyl acrylate when Z is an oxygen atom.

The monomers containing a tertiary amino group are then quaternized in a known manner, methyl chloride, dimethyl sulfate or diethyl sulfate being particularly suitable as alkylating reagents. The quaternization reaction can be carried out in aqueous solution or in the solvent.

Advantageously, such monomers of formula (ZI), which are derivatives of acrylamide or methacrylamide. Preference is furthermore given to those monomers which contain halide, methoxysulfate or ethoxysulfate ions as counterions. Also preferred are those monomers of the formula (ZI) in which R ³ , R ⁴ and R ^{5 are} methyl groups.

The acrylamidopropyltrimethylammonium chloride is a most preferred monomer of formula (Z-I).

Suitable monomeric carboxylic acids of the formula (Z-II) are acrylic acid, methacrylic acid, crotonic acid and 2-methylcrotonic acid. Preference is given to using acrylic or methacrylic acid, in particular acrylic acid.

The zwitterionic polymers which can be used according to the invention are prepared from monomers of the formulas (Z-I) and (Z-II) by polymerization processes known per se. The polymerization can be carried out either in aqueous or aqueous-alcoholic solution. The alcohols used are alcohols having 1 to 4 carbon atoms, preferably isopropanol, which simultaneously serve as polymerization regulators. However, other components than regulators may also be added to the monomer solution, eg. For example, formic acid or mercaptans, such as thioethanol and thioglycolic acid. The initiation of the polymerization takes place with the aid of free-radical-forming substances. For this purpose, redox systems and / or thermally decomposing radical formers of the azo compound type, such. As azoisobutyronitrile, azo-bis (cyanopentanoic acid) or azo-bis (amidinopropane) dihydrochloride can be used. As redox systems are z. B. combinations of hydrogen peroxide, potassium or ammonium peroxodisulfate and tertiary butyl hydroperoxide with sodium sulfite, sodium dithionite or hydroxylamine hydrochloride as a reduction component.

The polymerization can be carried out isothermally or under adiabatic conditions, depending on the concentration ratios by the heat of polymerization released, the temperature range for the course of the reaction between 20 and 200 ° C may vary, and the reaction may be carried out under the autogenous pressure. Preferably, the reaction temperature is between 20 and 100 ° C.

The pH during the copolymerization may vary within a wide range. Advantageously, polymerization is carried out at low pH values; however, pH values above the neutral point are also possible. After the polymerization is treated with an aqueous base, for. As sodium hydroxide, potassium hydroxide or ammonia, to a pH between 5 and 10, preferably 6 to 8 set. Further details of the polymerization process can be found in the examples.

Be particularly effective, such polymers have been found in which the monomers of the formula (Z-I) were present in excess over the monomers of formula (Z-II). It is therefore preferred according to the invention to use those polymers which consist of monomers of the formula (ZI) and the monomers of the formula (Z-II) in a molar ratio of 60:40 to 95: 5, in particular from 75:25 to 95: 5 , consist.

• A) Monomeren mit quartären Ammoniumgruppen der allgemeinen Formel (Z-I), R¹-CH=CR²-CO-Z-(C_nH_2n)-N⁽⁺⁾R³R⁴R⁵ A^(–) (Z-I) in der R¹ und R² unabhängig voneinander stehen für Wasserstoff oder eine Methylgruppe und R³, R⁴ und R⁵ unabhängig voneinander für Alkylgruppen mit 1 bis 4 Kohlenstoff-Atomen, Z eine NH-Gruppe oder ein Sauerstoffatom, n eine ganze Zahl von 2 bis 5 und A^(–) das Anion einer organischen oder anorganischen Säure ist und
• B) monomeren Carbonsäuren der allgemeinen Formel (Z-II), R⁶-CH=CR⁷-COOH (Z-II) in der R⁶ und R⁷ unabhängig voneinander Wasserstoff oder Methylgruppen sind.

Agents preferred according to the invention are characterized in that the amphoteric polymer (s) comprise monomers A) and B), wherein A) and B) are selected from

• A) monomers having quaternary ammonium groups of the general formula (ZI), R ¹ -CH = CR ² -CO-Z- (C _n H _2n ) -N ⁽⁺⁾ R ³ R ⁴ R ⁵ A ^(-) (ZI) in which R ¹ and R ² independently of one another are hydrogen or a methyl group and R ³ , R ⁴ and R ⁵ are each independently alkyl groups having 1 to 4 carbon atoms, Z is an NH group or an oxygen atom, n is an integer of 2 to 5 and A ^{(-) is} the anion of an organic or inorganic acid and
• B) monomeric carboxylic acids of the general formula (Z-II), R ⁶ -CH = CR ⁷ -COOH (Z-II) in which R ⁶ and R ^{7 are} independently hydrogen or methyl groups.

With particular preference, the amphoteric polymers used in the agents according to the invention contain monomers from the group of the acrylamides and / or methacrylamides with alkylammonium groups. Acrylic acid and / or methacrylic acid and / or crotonic acid and / or 2-methyl-crotonic acid have proven useful as monomers with anionic groups which are additionally present in the polymers.

• – Trimethylammoniumethylacrylamid und/oder,
• – Trimethylammoniumethylmethacrylamid und/oder
• – Trimethylammoniumpropylacrylamid und/oder
• – Trimethylammoniumpropylmethacrylamid und/oder
• – Trimethylammoniumethylacrylamid und/oder
• – Trimethylammoniumethylacrylat und/oder
• – Trimethylammoniumethylmethacrylat und/oder
• – Trimethylammoniumethylacrylat und/oder
• – Ethyldimethylammoniumethylacrylamid und/oder,
• – Ethyldimethylammoniumethylmethacrylamid und/oder
• – Ethyldimethylammoniumpropylacrylamid und/oder
• – Ethyldimethylammoniumpropylmethacrylamid und/oder
• – Ethyldimethylammoniumethylacrylamid und/oder
• – Ethyldimethylammoniumethylacrylat und/oder
• – Ethyldimethylammoniumethylmethacrylat und/oder
• – Ethyldimethylammoniumethylacrylat mit mindestens einem der Monomere
• – Acrylsäure und/oder
• – Methacrylsäure und/oder
• – Crotonsäure und/oder
• – 2-Methyl-crotonsäure sind.

In summary, agents according to the invention are preferred in which the amphoteric polymer (s) are co-polymers of at least one of the monomers

• Trimethylammoniumethylacrylamide and / or
• - Trimethylammoniumethylmethacrylamid and / or
• - trimethylammoniumpropylacrylamide and / or
• - Trimethylammoniumpropylmethacrylamid and / or
• - Trimethylammoniumethylacrylamid and / or
• - Trimethylammoniumethylacrylat and / or
• - Trimethylammoniumethylmethacrylat and / or
• - Trimethylammoniumethylacrylat and / or
• Ethyldimethylammoniumethylacrylamide and / or
• - Ethyldimethylammoniumethylmethacrylamid and / or
• Ethyldimethylammoniumpropylacrylamide and / or
• Ethyldimethylammoniumpropylmethacrylamide and / or
• - Ethyldimethylammoniumethylacrylamid and / or
• - Ethyldimethylammoniumethylacrylat and / or
• - Ethyldimethylammoniumethylmethacrylat and / or
• - Ethyldimethylammoniumethylacrylat with at least one of the monomers
• - acrylic acid and / or
• - methacrylic acid and / or
• - Crotonic acid and / or
• Are 2-methyl crotonic acid.

• – Copolymere von Trimethylammoniumethylacrylamid mit Acrylsäure
• – Copolymere von Trimethylammoniumethylacrylamid mit Methacrylsäure
• – Copolymere von Trimethylammoniumethylacrylamid mit Crotonsäure
• – Copolymere von Trimethylammoniumethylacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Trimethylammoniumethylmethacrylamid mit Acrylsäure
• – Copolymere von Trimethylammoniumethylmethacrylamid mit Methacrylsäure
• – Copolymere von Trimethylammoniumethylmethacrylamid mit Crotonsäure
• – Copolymere von Trimethylammoniumethylmethacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Trimethylammoniumpropylacrylamid mit Acrylsäure
• – Copolymere von Trimethylammoniumpropylacrylamid mit Methacrylsäure
• – Copolymere von Trimethylammoniumpropylacrylamid mit Crotonsäure
• – Copolymere von Trimethylammoniumpropylacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Trimethylammoniumpropylmethacrylamid mit Acrylsäure
• – Copolymere von Trimethylammoniumpropylmethacrylamid mit Methacrylsäure
• – Copolymere von Trimethylammoniumpropylmethacrylamid mit Crotonsäure
• – Copolymere von Trimethylammoniumpropylmethacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Trimethylammoniumethylacrylamid mit Acrylsäure
• – Copolymere von Trimethylammoniumethylacrylamid mit Methacrylsäure
• – Copolymere von Trimethylammoniumethylacrylamid mit Crotonsäure
• – Copolymere von Trimethylammoniumethylacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Trimethylammoniumethylacrylat mit Acrylsäure
• – Copolymere von Trimethylammoniumethylacrylat mit Methacrylsäure
• – Copolymere von Trimethylammoniumethylacrylat mit Crotonsäure
• – Copolymere von Trimethylammoniumethylacrylat mit 2-Methyl-crotonsäure
• – Copolymere von Trimethylammoniumethylmethacrylat mit Acrylsäure
• – Copolymere von Trimethylammoniumethylmethacrylat mit Methacrylsäure
• – Copolymere von Trimethylammoniumethylmethacrylat mit Crotonsäure
• – Copolymere von Trimethylammoniumethylmethacrylat mit 2-Methyl-crotonsäure
• – Copolymere von Trimethylammoniumethylacrylat mit Acrylsäure
• – Copolymere von Trimethylammoniumethylacrylat mit Methacrylsäure
• – Copolymere von Trimethylammoniumethylacrylat mit Crotonsäure
• – Copolymere von Trimethylammoniumethylacrylat mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylamid mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylamid mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylamid mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumpropylacrylamid mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumpropylacrylamid mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumpropylacrylamid mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumpropylacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumpropylmethacrylamid mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumpropylmethacrylamid mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumpropylmethacrylamid mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumpropylmethacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylamid mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylat mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylat mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylat mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumethylmethacrylat mit 2-Methyl-crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit Acrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit Methacrylsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit Crotonsäure
• – Copolymere von Ethyldimethylammoniumethylacrylat mit 2-Methyl-crotonsäure

Particularly preferred amphoteric polymers according to the invention are:

• - Copolymers of trimethylammoniumethylacrylamide with acrylic acid
• - Copolymers of trimethylammoniumethylacrylamide with methacrylic acid
• - Copolymers of trimethylammoniumethylacrylamide with crotonic acid
• - Copolymers of trimethylammoniumethylacrylamide with 2-methyl-crotonic acid
• - Copolymers of trimethylammoniumethylmethacrylamide with acrylic acid
• - Copolymers of trimethylammoniumethylmethacrylamide with methacrylic acid
• - Copolymers of trimethylammoniumethylmethacrylamide with crotonic acid
• - Copolymers of trimethylammoniumethylmethacrylamide with 2-methyl-crotonic acid
• - Copolymers of trimethylammoniumpropylacrylamide with acrylic acid
• - Copolymers of trimethylammoniumpropylacrylamide with methacrylic acid
• - Copolymers of trimethylammoniumpropylacrylamide with crotonic acid
• - Copolymers of trimethylammoniumpropylacrylamide with 2-methyl-crotonic acid
• - Copolymers of trimethylammoniumpropylmethacrylamide with acrylic acid
• - Copolymers of trimethylammoniumpropylmethacrylamide with methacrylic acid
• - Copolymers of trimethylammoniumpropylmethacrylamide with crotonic acid
• - Copolymers of trimethylammonium propylmethacrylamide with 2-methyl-crotonic acid
• - Copolymers of trimethylammoniumethylacrylamide with acrylic acid
• - Copolymers of trimethylammoniumethylacrylamide with methacrylic acid
• - Copolymers of trimethylammoniumethylacrylamide with crotonic acid
• - Copolymers of trimethylammoniumethylacrylamide with 2-methyl-crotonic acid
• - Copolymers of trimethylammonium ethyl acrylate with acrylic acid
• - Copolymers of trimethylammonium ethyl acrylate with methacrylic acid
• - Copolymers of trimethylammonium ethyl acrylate with crotonic acid
• - Copolymers of trimethylammonium ethyl acrylate with 2-methyl-crotonic acid
• - Copolymers of trimethylammonium ethyl methacrylate with acrylic acid
• - Copolymers of trimethylammoniumethyl methacrylate with methacrylic acid
• - Copolymers of trimethylammonium ethyl methacrylate with crotonic acid
• - Copolymers of trimethylammonium ethyl methacrylate with 2-methyl-crotonic acid
• - Copolymers of trimethylammonium ethyl acrylate with acrylic acid
• - Copolymers of trimethylammonium ethyl acrylate with methacrylic acid
• - Copolymers of trimethylammonium ethyl acrylate with crotonic acid
• - Copolymers of trimethylammonium ethyl acrylate with 2-methyl-crotonic acid
• - Copolymers of Ethyldimethylammoniumethylacrylamid with acrylic acid
• - Copolymers of ethyldimethylammoniumethylacrylamide with methacrylic acid
• - Copolymers of ethyldimethylammoniumethylacrylamide with crotonic acid
• - Copolymers of Ethyldimethylammoniumethylacrylamid with 2-methyl crotonic acid
• - Copolymers of Ethyldimethylammoniumethylmethacrylamid with acrylic acid
• - Copolymers of ethyldimethylammoniumethylmethacrylamide with methacrylic acid
• - Copolymers of ethyldimethylammoniumethylmethacrylamide with crotonic acid
• - Copolymers of Ethyldimethylammoniumethylmethacrylamid with 2-methyl-crotonic acid
• - Copolymers of ethyldimethylammoniumpropylacrylamide with acrylic acid
• - Copolymers of ethyldimethylammoniumpropylacrylamide with methacrylic acid
• Copolymers of ethyldimethylammoniumpropylacrylamide with crotonic acid
• - Copolymers of ethyldimethylammoniumpropylacrylamide with 2-methyl-crotonic acid
• - Copolymers of ethyldimethylammoniumpropylmethacrylamide with acrylic acid
• - Copolymers of ethyldimethylammoniumpropylmethacrylamide with methacrylic acid
• Copolymers of ethyldimethylammoniumpropylmethacrylamide with crotonic acid
• - Copolymers of ethyldimethylammoniumpropylmethacrylamide with 2-methyl-crotonic acid
• - Copolymers of Ethyldimethylammoniumethylacrylamid with acrylic acid
• - Copolymers of ethyldimethylammoniumethylacrylamide with methacrylic acid
• - Copolymers of ethyldimethylammoniumethylacrylamide with crotonic acid
• - Copolymers of Ethyldimethylammoniumethylacrylamid with 2-methyl crotonic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with acrylic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with methacrylic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with crotonic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with 2-methyl-crotonic acid
• - Copolymers of ethyldimethylammoniumethyl methacrylate with acrylic acid
• - Copolymers of ethyldimethylammonium ethyl methacrylate with methacrylic acid
• - Copolymers of ethyldimethylammonium ethyl methacrylate with crotonic acid
• - Copolymers of ethyldimethylammoniumethyl methacrylate with 2-methyl-crotonic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with acrylic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with methacrylic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with crotonic acid
• - Copolymers of ethyldimethylammonium ethyl acrylate with 2-methyl-crotonic acid

As a further ingredient, the agents according to the invention may with particular preference contain one or more amino acids. Amino acids which can be used particularly preferably according to the invention are selected from the group glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-sulfoxide (L-alliin), L-trans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.

Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here, preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1.5 Wt .-%, more preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group of glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.

Another preferred group of ingredients of the compositions of the invention are vitamins, provitamins or vitamin precursors. These are described below:
The group of substances called vitamin A includes retinol (vitamin A ₁ ) and 3,4-didehydroretinol (vitamin A ₂ ). The β-carotene is the provitamin of retinol. As vitamin A component according to the invention, for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration. The agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.

• – Vitamin B₁ (Thiamin)
• – Vitamin B₂ (Riboflavin)
• – Vitamin B₃. Unter dieser Bezeichnung werden häufig die Verbindungen Nicotinsäure und Nicotinsäureamid (Niacinamid) geführt. Erfindungsgemäß bevorzugt ist das Nicotinsäureamid, das in den erfindungsgemäß verwendeten Mitteln bevorzugt in Mengen von 0,05 bis 1 Gew.-%, bezogen auf das gesamte Mittel, enthalten ist.
• – Vitamin B₅ (Pantothensäure, Panthenol und Pantolacton). Im Rahmen dieser Gruppe wird bevorzugt das Panthenol und/oder Pantolacton eingesetzt. Erfindungsgemäß einsetzbare Derivate des Panthenols sind insbesondere die Ester und Ether des Panthenols sowie kationisch derivatisierte Panthenole. Einzelne Vertreter sind beispielsweise das Panthenoltriacetat, der Panthenolmonoethylether und dessen Monoacetat sowie die in der WO 92/13829 offenbarten kationischen Panthenolderivate. Die genannten Verbindungen des Vitamin B₅-Typs sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05–10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,1–5 Gew.-% sind besonders bevorzugt.
• – Vitamin B₆ (Pyridoxin sowie Pyridoxamin und Pyridoxal).

The vitamin B group or the vitamin B complex include, among others

• - Vitamin B ₁ (thiamine)
• - Vitamin B ₂ (riboflavin)
• - Vitamin B ₃ . Under this name, the compounds nicotinic acid and nicotinamide (niacinamide) are often performed. Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
• - Vitamin B ₅ (pantothenic acid, panthenol and pantolactone). Panthenol and / or pantolactone are preferably used in the context of this group. Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are for example the Panthenoltriacetat, the Panthenolmonoethylether and its monoacetate as well as in the WO 92/13829 disclosed cationic panthenol derivatives. The said compounds of the vitamin B ₅ type are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
• - Vitamin B ₆ (pyridoxine and pyridoxamine and pyridoxal).

Vitamin C (ascorbic acid). Vitamin C is used in the agents according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.

Vitamin E (tocopherols, especially α-tocopherol). Tocopherol and its derivatives, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent. Vitamin F. The term "vitamin F" is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.

Vitamin H. Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] -imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile become established. Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.

In summary, hair treatment compositions according to the invention are preferred which additionally contain as care substance - based on its weight - 0.1 to 5 wt .-%, preferably 0.2 to 4 wt .-%, particularly preferably 0.25 to 3.5 wt .-% , more preferably 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors containing, preferably, the groups A, B, C, E, Panthenol ((±) -2,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethyl-butyramide, provitamin B ₅ ) and / or pantothenic acid (vitamin B ₃ , Vitamin B ₅ ) and / or niacin, niacinamide or nicotinamide (vitamin B ₃ ) and / or L-ascorbic acid (vitamin C) and / or thiamine (vitamin B ₁ ) and / or riboflavin (vitamin B ₂ , vitamin G) and / or biotin (vitamin B ₇ , vitamin H) and / or folic acid (vitamin B ₉ , vitamin B _c or vitamin M) and / or vitamin B ₆ and / or vitamin B ₁₂ .

To improve the elasticity and strengthen the internal structure of the hair treated with the agents according to the invention, the compositions according to the invention may contain purine and / or purine derivatives. In particular, the combination of purine and / or purine derivatives with ubiquinones and / or plastoquinones results in that the hairs treated with appropriate agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.

• – Monosachhariden, insbesondere
• – D-Ribose und/oder
• – D-Xylose und/oder
• – L-Arabinose und/oder
• – D-Glucose und/oder
• – D-Mannose und/oder
• – D-Galactose und/oder
• – D-Fructose und/oder
• – Sorbose und/oder
• – L-Fucose und/oder
• – L-Rhamnose
• – Disacchariden, insbesondere
• – Saccharose und/oder
• – Maltose und/oder
• – Lactose und/oder
• – Trehalose und/oder
• – Cellobiose und/oder
• – Gentiobiose und/oder
• – Isomaltose.

As a further component, the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides. Here are preferred hair treatment compositions according to the invention characterized in that they are used as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt. -%, more preferably 0.5 to 3.5 wt .-% and in particular 0.75 to 2.5 wt .-% carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides containing preferred carbohydrates are selected out

• - Monosaccharides, in particular
• D-ribose and / or
• - D-xylose and / or
• - L-arabinose and / or
• D-glucose and / or
• - D-mannose and / or
• D-galactose and / or
• - D-fructose and / or
• - sorbose and / or
• - L-fucose and / or
• - L-rhamnose
• - Disaccharides, in particular
• - sucrose and / or
• - maltose and / or
• - lactose and / or
• - Trehalose and / or
• Cellobiose and / or
• - Gentiobiose and / or
• - Isomaltose.

• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Glucosemonohydrat,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Saccharose,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Fructose.

Particularly preferred agents according to the invention contain based on their weight

• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose.

As already mentioned, preferred agents according to the invention contain (a) amino acid (s).

Amino acids which can be used particularly preferably according to the invention are selected from the group glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-sulfoxide (L-alliin), L-trans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.

Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here, according to the invention, preferred cosmetic agents are characterized in that they additionally contain from 0.05 to 5% by weight, preferably from 0.1 to 2.5% by weight, more preferably from 0.15 to 1% by weight and in particular from 0 , 2 to 0.5 wt .-% amino acid (s), preferably (one) amino acid (s) from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.

• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Glucosemonohydrat und 0,1 bis 0,25 Gew.-% Glycin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Saccharose und 0,1 bis 0,25 Gew.-% Glycin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Fructose und 0,1 bis 0,25 Gew.-% Glycin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Glucosemonohydrat und 0,1 bis 0,25 Gew.-% Alanin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Saccharose und 0,1 bis 0,25 Gew.-% Alanin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Fructose und 0,1 bis 0,25 Gew.-% Alanin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Glucosemonohydrat und 0,1 bis 0,25 Gew.-% Valin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Saccharose und 0,1 bis 0,25 Gew.-% Valin,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Fructose und 0,1 bis 0,25 Gew.-% Valin.

Particularly preferred agents according to the invention contain based on their weight

• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of glycine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of glycine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of glycine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of alanine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of alanine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of alanine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of valine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of valine,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of valine.

in welchen die Reste R¹ bis R¹⁰ unabhängig voneinander stehen für:

• – Wasserstoff, -OH, einen Methyl-, Methoxy-, Aminomethyl- oder Hydroxymethylrest,
• – -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest,
• – -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest,
• – eine Gruppe -OR¹¹, mit R¹¹ als einem -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -NR¹²R¹³, wobei R¹² und R¹³ jeweils unabhängig voneinander stehen für Wasserstoff, einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -COOR¹⁴, wobei R¹⁴ steht für Wasserstoff, einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest,
• – eine Gruppe -CONR¹⁵R¹⁶, wobei R¹⁵ und R¹⁶ jeweils stehen für Wasserstoff, Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest,
• – eine Gruppe -COR¹⁶, wobei R¹⁶ steht für einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest,
• – eine Gruppe -OCOR¹⁷, wobei R¹⁷ steht für einen Methyl-, einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Mono-, Di-, Tri- oder Polyhydroxykohlenwasserstoffrest, einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Mono-, Di-, Tri- oder Polyaminokohlenwasserstoffrest,

mit der Maßgabe, daß für den Fall, wenn R⁷ und R⁸ für -OH und gleichzeitig R⁹ oder R¹⁰ für Wasserstoff stehen, die verbleibende Gruppe R⁹ oder R¹⁰ nicht für einen Dihydroxyethylrest steht. Agents preferred according to the invention contain as care substance - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7.5% by weight and in particular 0.5 to 5% by weight of at least one 2-furanone derivative of the formula (Fur-I) and / or of the formula (Fur-II)

in which the radicals R ¹ to R ^{10 are} independently of one another

• Hydrogen, -OH, a methyl, methoxy, aminomethyl or hydroxymethyl radical,
• --C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear hydrocarbon radical,
• - C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear mono-, di- or Trihydroxykohlenwasserstoffrest,
• --C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
• - a group -OR ¹¹ , with R ¹¹ as a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbyl radical,
• - a group -NR ¹² R ¹³ , wherein R ¹² and R ¹³ each independently represent hydrogen, a methyl, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
• A group -COOR ¹⁴ , where R ¹⁴ is hydrogen, a methyl, a C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ -saturated hydrocarbon radical, or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbyl radical,
• - a group -CONR ¹⁵ R ¹⁶ , wherein R ¹⁵ and R ¹⁶ each represent hydrogen, methyl, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ - saturated mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbon hydrocarbon radical, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
• A group -COR ¹⁶ , where R ¹⁶ is a methyl, a C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ -saturated or -or- or di-unsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
• - a group -OCOR ¹⁷ , wherein R ¹⁷ is a methyl, a -C ₂ -C ₃₀ -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₃₀ -saturated or one or polyunsaturated, branched or linear mono-, di-, tri- or polyhydroxy hydrocarbon radical, a -C ₂ -C ₃₀ -saturated or mono- or polyunsaturated, branched or linear mono-, di-, tri- or polyamino hydrocarbon radical,

with the proviso that when R ⁷ and R ^{8 are} -OH and at the same time R ⁹ or R ^{10 is} hydrogen, the remaining group R ⁹ or R ¹⁰ does not represent a dihydroxyethyl radical.

The compounds of the formulas (Fur-I) and (Fur-II) are used as intermediates in the synthesis of natural products and in the preparation of medicaments and vitamins. The preparation of the active compounds according to the formulas (Fur-I) and (Fur-II) can be carried out, for example, by reacting primary alcohols with acrylic acids. Furthermore, compounds of the formula (Fur-I) are obtained by reactions starting from hydroxypivaldehyde. Also, carbonylations of alkynes lead to substituted 2-furanones of the formula (Fur-I) or (Fur-II). Finally, the compounds of the formula (Fur-I) or of the formula (Fur-II) can be obtained by intramolecular esterification of the corresponding hydroxycarboxylic acids. For example, the following compounds are obtained in one of the previously identified synthetic routes: 2,5-dihydro-5-methoxy-2-furanone, tetrahydro-5-oxo-2-furancarboxylic acid, dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone, or 3,4-dimethyl-5-pentylidenedihydro-2 (5H) -furanone or 4-hydroxy-2,5-dimethyl-3 (2H) -furanone. Of course, the 2-furanones according to the invention include all possible stereoisomers as well as their mixtures. By the 2-furanones according to the invention, the odor of the cosmetic agent is not permanently affected, so that a perfuming of the agent must be done separately.

• – Wasserstoff, einen -OH-, einen Methyl-, Methoxy-, Aminomethyl-, Hydroxymethylrest,
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest,
• – eine Gruppe -OR¹¹, mit R¹¹ als einem -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -NR¹²R¹³, wobei R¹² und R¹³ jeweils unabhängig voneinander stehen für Wasserstoff, einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -COOR¹⁴, wobei R¹⁴ steht für Wasserstoff, einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest,
• – eine Gruppe -COR¹⁶, wobei R¹⁶ steht für einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest,
• – eine Gruppe -OCOR¹⁷, wobei R¹⁷ steht für einen Methyl-, einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Mono-, Di-, Tri- oder Polyhydroxyalkylrest, oder einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Mono-, Di-, Tri- oder Polyaminokohlenwasserstoffrest.

Preferred compounds of the formula (fur-I) and / or of the formula (fur-II) may be compounds in which the substituents R ¹ , R ² and R ⁷ independently of one another represent:

• Hydrogen, an -OH, a methyl, methoxy, aminomethyl, hydroxymethyl radical,
• A C ₂ -C ₄ saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical,
• A C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
• - a group -OR ¹¹ , with R ¹¹ as a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbyl radical,
• - a group -NR ¹² R ¹³ , wherein R ¹² and R ¹³ each independently represent hydrogen, a methyl, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
• A group -COOR ¹⁴ , wherein R ¹⁴ is hydrogen, a methyl, a C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ -saturated or - or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
• A group -COR ¹⁶ , where R ¹⁶ is a methyl, a C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ -saturated or -or- or di-unsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical, a -C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon radical,
• - a group -OCOR ¹⁷ , wherein R ¹⁷ is a methyl, a -C ₂ -C ₃₀ -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₃₀ -saturated or one or polyunsaturated, branched or linear mono-, di-, tri- or polyhydroxyalkyl radical, or a -C ₂ -C ₃₀ -saturated or mono- or polyunsaturated, branched or linear mono-, di-, tri- or polyamino hydrocarbon radical.

• – Wasserstoff, einen -OH-, einen Methyl-, Methoxy-, Aminomethyl-, Hydroxymethylrest,
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest,
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest oder
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest.

In a further embodiment of the teaching according to the invention, it has been found that in the case of the compounds of the formula (Fur-I) or of the formula (Fur-II), the radicals R ³ , R ⁴ and R ^{8 are} preferably, independently of one another,

• Hydrogen, an -OH, a methyl, methoxy, aminomethyl, hydroxymethyl radical,
• A C ₂ -C ₄ saturated or mono- or diunsaturated, branched or linear hydrocarbon radical,
• - a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical or
• - a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon.

• – Wasserstoff, einen -OH-, einen Methyl-, Methoxy-, Aminomethyl-, Hydroxymethylrest,
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest,
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest oder
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Triaminokohlenwasserstoffrest.

Furthermore, it may be preferred for the radicals R ⁵ , R ⁶ , R ⁹ and R ¹⁰ in the active substance according to the formula (I) and / or formula (II) according to the invention independently of one another to be:

• Hydrogen, an -OH, a methyl, methoxy, aminomethyl, hydroxymethyl radical,
• A C ₂ -C ₄ saturated or mono- or diunsaturated, branched or linear hydrocarbon radical,
• - a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical or
• - a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear mono-, di- or triaminocarbon.

• – Wasserstoff, einen -OH-, einen Methyl-, Methoxy-, Aminomethyl-, Hydroxymethylrest,
• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -OR¹¹, mit R¹¹ als einem -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -COOR¹⁴, wobei R¹⁴ steht für Wasserstoff, einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -COR¹⁶, wobei R¹⁶ steht für einen Methyl-, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -OCOR¹⁷, wobei R¹⁷ steht für einen Methyl-, einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, einen -C₂-C₃₀- gesättigten oder ein- oder mehrfach ungesättigten, verzweigten oder linearen Mono-, Di-, Tri- oder Polyhydroxykohlenwasserstoffrest.

In a particularly preferred embodiment of the teaching according to the invention, a compound of the formula (Fur-I) is used. It may be preferred that in a compound of the formula (fur-I), the radicals R ¹ and R ^{2 are} independently of one another:

• Hydrogen, an -OH, a methyl, methoxy, aminomethyl, hydroxymethyl radical,
• A C ₂ -C ₄ saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical,
• - a group -OR ¹¹ , with R ¹¹ as a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbyl radical,
• A group -COOR ¹⁴ , where R ¹⁴ is hydrogen, a methyl, a C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ -saturated hydrocarbon radical, or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
• A group -COR ¹⁶ , where R ¹⁶ is a methyl, a C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ -saturated or -or- or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
• - a group -OCOR ¹⁷ , wherein R ¹⁷ is a methyl, a -C ₂ -C ₃₀ -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₃₀ -saturated or one or polyunsaturated, branched or linear mono-, di-, tri- or Polyhydroxykohlenwasserstoffrest.

Furthermore, in this particularly preferred embodiment of the teaching according to the invention, it may be advantageous if in the compounds of the formula (Fur-I) the radicals R ³ and R ⁴ independently of one another represent:

• Hydrogen, an -OH, a methyl, methoxy, aminomethyl, hydroxymethyl radical,
• A C ₂ -C ₄ saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical,
• - a group -OR ¹¹ , with R ¹¹ as a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbyl radical,
• A group -COOR ¹⁴ , where R ¹⁴ is hydrogen, a methyl, a C ₂ -C ₄ -saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₄ -saturated hydrocarbon radical, or diunsaturated, branched or linear mono-, di- or trihydroxyhydrocarbyl radical,
• - a group -OCOR ¹⁷ , wherein R ¹⁷ is a methyl, a -C ₂ -C ₃₀ -saturated or mono- or polyunsaturated, branched or linear hydrocarbon radical, a -C ₂ -C ₃₀ -saturated or one or polyunsaturated, branched or linear mono-, di-, tri- and / or polyhydroxy hydrocarbon radical.

• – einen -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest,
• – eine Gruppe -OR¹¹, mit R¹¹ als einem -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Kohlenwasserstoffrest, -C₂-C₄- gesättigten oder ein- oder zweifach ungesättigten, verzweigten oder linearen Mono-, Di- oder Trihydroxykohlenwasserstoffrest.

In this preferred embodiment, it may furthermore be advantageous for the compounds of the formula (Fur I) for the radicals R 5 and R 6 to stand independently for:

• A C ₂ -C ₄ saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy hydrocarbon radical,
• - a group -OR ¹¹ , with R ¹¹ as a -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear hydrocarbon radical, -C ₂ -C ₄ - saturated or mono- or diunsaturated, branched or linear Mono-, di- or trihydroxyhydrocarbon radical.

• – (R)-(-)-4-Hydroxymethyl-γ-butyrolacton und/oder
• – D,L-4-Hydroxymethyl-γ-butyrolacton und/oder
• – (S)-(+)-4-Hydroxymethyl-γ-butyrolacton und/oder
• – R-(-)-2-Hydroxy-3,3-dimethyl-γ-butyrolacton und/oder
• – D,L-2-Hydroxy-3,3-dimethyl-γ-butyrolacton und/oder
• – S(+)-2-Hydroxy-3,3-dimethyl-γ-butyrolacton und/oder
• – 4-Hydroxy-2,5-dimethyl-3(2H)-furanon und/oder
• – Tetrahydro-5-oxo-2-furancarbonsäure und/oder
• – Tetrahydro-5-oxo-2-furancarbonsäure, Na-Salz und/oder
• – Tetrahydro-5-oxo-2-furancarbonsäure, K-Salz und/oder
• – 2,5-Dihydro-5-methoxy-2-furanon und/oder
• – Dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanon

eingesetzt. In einer ganz besonders bevorzugten Ausführungsform der erfindungsgemäßen Lehre wird als Verbindung entsprechend der Formel (Fur-I) Dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanon eingesetzt. In a particularly preferred embodiment of the teaching according to the invention is used as the compound according to the formula (Fur-I)

• - (R) - (-) - 4-hydroxymethyl-γ-butyrolactone and / or
• - D, L-4-hydroxymethyl-γ-butyrolactone and / or
• - (S) - (+) - 4-hydroxymethyl-γ-butyrolactone and / or
• - R - (-) - 2-hydroxy-3,3-dimethyl-γ-butyrolactone and / or
• - D, L-2-hydroxy-3,3-dimethyl-γ-butyrolactone and / or
• - S (+) - 2-hydroxy-3,3-dimethyl-γ-butyrolactone and / or
• 4-hydroxy-2,5-dimethyl-3 (2H) -furanone and / or
• - Tetrahydro-5-oxo-2-furancarbonsäure and / or
• - Tetrahydro-5-oxo-2-furancarbonsäure, Na salt and / or
• Tetrahydro-5-oxo-2-furancarboxylic acid, K salt and / or
• 2,5-dihydro-5-methoxy-2-furanone and / or
• Dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone

used. In a very particularly preferred embodiment of the teaching according to the invention is used as a compound corresponding to the formula (Fur-I) dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone.

Another, more preferably usable care substance which has activating properties is taurine. According to the invention, preferred hair-treatment compositions contain as care substance - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7.5% by weight and in particular 0.5 to 5% by weight of taurine (2-aminoethanesulfonic acid).

enthalten. Preference is also given to the additional use of bisabolol and / or bisabolol oxides in the agents according to the invention. Here, hair treatment compositions according to the invention are preferred which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1.5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol

contain.

The agents of the present invention may contain, in addition to the oligopeptide (s), hyaluronic acid ester (s) and optional other ingredients, other substances that prevent, ameliorate or cure hair loss. In particular, a content of hair root stabilizing agents is advantageous. These substances are described below:
Propecia (Finasteride) is currently the only preparation that is approved worldwide and has been proven in many studies to be effective and tolerable. Propecia causes less DHT to form from testosterone.

Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. For the treatment of hair loss, it may only be used for external application. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil. The effectiveness increases with the dosage, in hair waters Minoxidil is only up to 5% share soluble. In many countries, hair tonic with up to 2% minoxidil content is available without prescription.

To combat the hormonal influences on the hair follicles spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application. Spironolactone acts as an androgen receptor blocker, ie. the binding of DHT to the hair follicles is prevented.

In summary, cosmetic agents according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.

Additional antidandruff active ingredients (for example climbazole, piroctone olamine or zinc pyrithione) are used to purposefully reduce the amount of dandruff causing the dandruff, to restore the normal bacterial count to the normal percentage and to reduce the scaling to the physiological level. However, laboratory tests have shown that the different species representatives of Pityrosporum ovale react differently to the antidandruff active ingredients. In order to maximally combat all dandruff is therefore a combination of anti-dandruff active ingredients most successful.

In summary, hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of antidandruff active ingredients, in particular piroctone olamine (1-hydroxy-4-methyl-6- (2,4,4-tri-methylpentyl) -pyridine-2 ( 1H) -one, compound with 2-aminoethanol, 1: 1) and / or zinc pyrithione and / or selenium sulfide and / or climbazole and / or salicylic acid or fumaric acid.

The compositions according to the invention may furthermore contain all active substances, additives and auxiliaries known for such preparations. In many cases, the agents contain at least one surfactant, wherein in principle both anionic and zwitterionic, ampholytic, nonionic and cationic surfactants are suitable. In many cases, however, it has proved to be advantageous to select the surfactants from anionic, zwitterionic or nonionic surfactants. These surfactants have been described in detail above.

• – Anlagerungsprodukte von 4 bis 30 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare Fettalkohole mit 8 bis 22 C-Atomen, an Fettsäuren mit 12 bis 22 C-Atomen und an Alkylphenole mit 8 bis 15 C-Atomen in der Alkylgruppe,
• – C₁₂-C₂₂-Fettsäuremono- und -diester von Anlagerungsprodukten von 1 bis 30 Mol Ethylenoxid an Polyole mit 3 bis 6 Kohlenstoffatomen, insbesondere an Glycerin,
• – Ethylenoxid- und Polyglycerin-Anlagerungsprodukte an Methylglucosid-Fettsäureester, Fettsäurealkanolamide und Fettsäureglucamide,
• – C₈-C₂₂-Alkylmono- und -oligoglycoside und deren ethoxylierte Analoga, wobei Oligomerisierungsgrade von 1,1 bis 5, insbesondere 1,2 bis 2,0, und Glucose als Zuckerkomponente bevorzugt sind,
• – Gemische aus Alkyl-(oligo)-glucosiden und Fettalkoholen zum Beispiel das im Handel erhältliche Produkt Montanov^®68,
• – Anlagerungsprodukte von 5 bis 60 Mol Ethylenoxid an Rizinusöl und gehärtetes Rizinusöl,
• – Partialester von Polyolen mit 3–6 Kohlenstoffatomen mit gesättigten Fettsäuren mit 8 bis 22 C-Atomen,
• – Sterine. Als Sterine wird eine Gruppe von Steroiden verstanden, die am C-Atom 3 des Steroid-Gerüstes eine Hydroxylgruppe tragen und sowohl aus tierischem Gewebe (Zoosterine) wie auch aus pflanzlichen Fetten (Phytosterine) isoliert werden. Beispiele für Zoosterine sind das Cholesterin und das Lanosterin. Beispiele geeigneter Phytosterine sind Ergosterin, Stigmasterin und Sitosterin. Auch aus Pilzen und Hefen werden Sterine, die sogenannten Mykosterine, isoliert.
• – Phospholipide. Hierunter werden vor allem die Glucose-Phospolipide, die z.B. als Lecithine bzw. Phospahtidylcholine aus z.B. Eidotter oder Pflanzensamen (z.B. Sojabohnen) gewonnen werden, verstanden.
• – Fettsäureester von Zuckern und Zuckeralkoholen, wie Sorbit,
• – Polyglycerine und Polyglycerinderivate wie beispielsweise Polyglycerinpoly-12-hydroxystearat (Handelsprodukt Dehymuls^® PGPH),
• – Lineare und verzweigte Fettsäuren mit 8 bis 30 C-Atomen und deren Na-, K-, Ammonium-, Ca-, Mg- und Zn-Salze.

In a further preferred embodiment, the agents according to the invention may contain emulsifiers (F). Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion. Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions. An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants. The selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion. Emulsifiers which can be used according to the invention are, for example

• Addition products of from 4 to 30 mol of ethylene oxide and / or from 0 to 5 mol of propylene oxide onto linear fatty alcohols having from 8 to 22 carbon atoms, to fatty acids containing from 12 to 22 carbon atoms and to alkylphenols having from 8 to 15 carbon atoms in the alkyl group,
• C ₁₂ -C ₂₂ -fatty acid mono- and diesters of addition products of from 1 to 30 mol of ethylene oxide onto polyols having from 3 to 6 carbon atoms, in particular to glycerol,
• Ethylene oxide and polyglycerol addition products to methyl glucoside fatty acid esters, fatty acid alkanolamides and fatty acid glucamides,
• C ₈ -C ₂₂ -alkylmono- and -oligoglycosides and their ethoxylated analogues, preference being given to degrees of oligomerization of from 1.1 to 5, in particular from 1.2 to 2.0, and glucose as the sugar component,
• Glucosides mixtures of alkyl (oligo) and fatty alcohols, for example, the commercially available product ^® Montanov 68, -
• Adducts of 5 to 60 moles of ethylene oxide with castor oil and hydrogenated castor oil,
• Partial esters of polyols having 3-6 carbon atoms with saturated fatty acids having 8 to 22 C atoms,
• - sterols. Sterols are understood to mean a group of steroids which have a hydroxyl group on C-atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are ergosterol, stigmasterol and sitosterol. Mushrooms and yeasts are also used to isolate sterols, the so-called mycosterols.
• - Phospholipids. These include, in particular, the glucose phospholipids which are obtained, for example, as lecithins or phosphatidylcholines from, for example, egg yolks or plant seeds (for example soybeans).
• Fatty acid esters of sugars and sugar alcohols, such as sorbitol,
• - polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate (commercial product Dehymuls ^® PGPH),
• - Linear and branched fatty acids with 8 to 30 carbon atoms and their Na, K, ammonium, Ca, Mg and Zn salts.

The agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.

The compositions according to the invention may preferably contain at least one nonionic emulsifier having an HLB value of 8 to 18. Nonionic emulsifiers with an HLB value of 10-15 may be particularly preferred according to the invention.

It has furthermore proven to be advantageous if, in addition to the polymer (s) from the group of cationic and / or amphoteric polymers, further polymers (G) are contained in the agents according to the invention. In a preferred embodiment, therefore, further polymers are added to the compositions according to the invention, both anionic and nonionic polymers having proven effective.

The anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups. Examples of anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid. The acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt. Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.

Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for all or some of the sulfonic acid group to be present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,

More preferably, the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid, which is available for example under the name Rheothik ^® 11-80 is commercially.

Within this embodiment, it may be preferable to use copolymers of at least one anionic monomer and at least one nonionic monomer. With regard to the anionic monomers, reference is made to the substances listed above. Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.

Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. A particularly preferred anionic Copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group is wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt. This copolymer may also be crosslinked, with crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used. Such a polymer is contained in the commercial product Sepigel ^® 305 from SEPPIC. The use of this compound, which in addition to the polymer component contains a hydrocarbon mixture (C ₁₃ -C ₁₄ isoparaffin) and a nonionic emulsifier (laureth-7), has proved to be particularly advantageous within the scope of the teaching according to the invention.

Also sold under the name Simulgel ^® 600 as a compound with isohexadecane and polysorbate-80 Natriumacryloyldimethyltaurat copolymers have proved to be particularly effective according to the invention.

Likewise preferred anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ^® commercially.

Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers. A 1.9-decadienes crosslinked maleic acid-methyl copolymer available under the name Stabileze® ^® QM.

In another embodiment, the agents according to the invention may contain nonionic polymers (G4).

• – Vinylpyrrolidon/Vinylester-Copolymere, wie sie beispielsweise unter dem Warenzeichen Luviskol^® (BASF) vertrieben werden. Luviskol^® VA 64 und Luviskol^® VA 73, jeweils Vinylpyrrolidon/Vinylacetat-Copolymere, sind ebenfalls bevorzugte nichtionische Polymere.
• – Celluloseether, wie Hydroxypropylcellulose, Hydroxyethylcellulose und Methylhydroxypropylcellulose, wie sie beispielsweise unter den Warenzeichen Culminal^® und Benecel^® (AQUALON) und Natrosol^®-Typen (Hercules) vertrieben werden.
• – Stärke und deren Derivate, insbesondere Stärkeether, beispielsweise Structure^® XL (National Starch), eine multifunktionelle, salztolerante Stärke;
• – Schellack
• – Polyvinylpyrrolidone, wie sie beispielsweise unter der Bezeichnung Luviskol^® (BASF) vertrieben werden.
• – Siloxane. Diese Siloxane können sowohl wasserlöslich als auch wasserunlöslich sein. Geeignet sind sowohl flüchtige als auch nichtflüchtige Siloxane, wobei als nichtflüchtige Siloxane solche Verbindungen verstanden werden, deren Siedepunkt bei Normaldruck oberhalb von 200 °C liegt. Bevorzugte Siloxane sind Polydialkylsiloxane, wie beispielsweise Polydimethylsiloxan, Polyalkylarylsiloxane, wie beispielsweise Polyphenylmethylsiloxan, ethoxylierte Polydialkylsiloxane sowie Polydialkylsiloxane, die Amin- und/oder Hydroxy-Gruppen enthalten.
• – Glycosidisch substituierte Silicone.

Suitable nonionic polymers are, for example:

• - Vinylpyrrolidone / vinyl ester copolymers, such as those sold under the trademark Luviskol ^® (BASF). Luviskol ^® VA 64 and Luviskol ^® VA 73, each vinylpyrrolidone / vinyl acetate copolymers, are also preferred nonionic polymers.
• - cellulose ethers such hydroxypropyl cellulose, hydroxyethyl cellulose and methylhydroxypropyl cellulose, as for example, under the trademark Culminal® ^® and Benecel ^® (AQUALON) and Natrosol ^® grades (Hercules) are distributed.
• - starch and its derivatives, in particular starch, such as Structure XL ^® (National Starch), a multifunctional, salt-tolerant starch;
• - shellac
• - polyvinylpyrrolidones, as for example under the name Luviskol ^® (BASF).
• - siloxanes. These siloxanes can be both water-soluble and water-insoluble. Both volatile and nonvolatile siloxanes are suitable, nonvolatile siloxanes being understood as meaning those compounds whose boiling point is above 200 ° C. under normal pressure. Preferred siloxanes are polydialkylsiloxanes, such as, for example, polydimethylsiloxane, polyalkylarylsiloxanes, such as, for example, polyphenylmethylsiloxane, ethoxylated polydialkylsiloxanes and polydialkylsiloxanes which contain amine and / or hydroxyl groups.
• - Glycosidically substituted silicones.

It is also possible according to the invention that the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.

The other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0.1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.

Furthermore, in a preferred embodiment of the invention, an agent according to the invention may also contain UV filters (I). The UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC (<280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.

The UV filters used according to the invention can be selected, for example, from substituted benzophenones, p-aminobenzoic acid esters, diphenylacrylic acid esters, cinnamic acid esters, salicylic acid esters, benzimidazoles and o-aminobenzoic acid esters.

Examples of UV filters which can be used according to the invention are 4-aminobenzoic acid, N, N, N-trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline-methylsulfate, 3,3,5-trimethyl-cyclohexylsalicylate (homosalates), 2-hydroxy-4-methoxy-benzophenone (benzophenone-3; Uvinul ^® M 40, Uvasorb MET ^{®, ®} Neo Heliopan BB, Eusolex ^® 4360), 2-phenylbenzimidazole-5-sulfonic acid and potassium, sodium and triethanolamine salts ( Phenylbenzimidazole Sulfonic Acid; Parsol ^® HS; Neo Heliopan Hydro ^®), 3,3 '- (1,4-phenylenedimethylene) -bis (7,7-dimethyl-2-oxo-bicyclo [2.2.1] hept-1- yl-methane sulfonic acid) and salts thereof, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) Methoxydibenzoylmethane -propane-1,3-dione (butyl; Parsol ^® 1789 Eusolex ^® 9020), α - (2-oxoborn-3-ylidene) toluene-4-sulfonic acid and salts thereof, ethoxylated 4-aminobenzoic acid ethyl ester (PEG-25 PABA; Uvinul ^® P 25), 4-dimethylaminobenzoic acid 2-ethylhexyl (octyl dimethyl PABA; Uvasorb ^® DMO, Escalol ^® 507, Eusolex ^® 6007), salicylic acid-2-ethylhexyl ester (octyl salicylate; Escalol ^® 587, Neo Heliopan ^® OS, Uvinul ^® O18), 4-methoxycinnamic acid isopentyl (isoamyl p-methoxycinnamate; Neo Heliopan ^® E 1000), 4-methoxycinnamic acid 2-ethylhexyl ester (Octyl Methoxycinnamate; Parsol ^® MCX, Escalol ^® 557, Neo Heliopan AV ^®), 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt (Benzophenone-4; Uvinul ^® MS 40; Uvasorb S 5 ^®), 3- (4'-methylbenzylidene) -D, L-camphor (4-methylbenzylidene camphor; Parsol ^® 5000, Eusolex ^® 6300), 3-benzylidene camphor (3-benzylidene camphor), 4-isopropylbenzyl, 2,4,6-trianilino- (p-carbo-2'- ethylhexyl-1'-oxi) -1,3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of N - {(2 and 4) - [2-oxoborn-3-ylidenemethyl] benzyl} acrylamide , 2,4-dihydroxy (benzophenone-1; Uvasorb ^® 20 H, Uvinul ^® 400), 1,1'-Diphenylacrylonitrilsäure-2-ethylhexyl ester (Octocrylene; Eusolex ^® OCR, Neo Heliopan ^® Type 303, Uvinul ^® N 539 SG), o-aminobenzoic acid menthyl ester (menthyl anthranilate; Neo Heli OPAN ^® MA), 2,2 ', 4,4'-tetrahydroxy benzophenone (benzophenone-2; Uvinul ^® D-50), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone (Benzophenone-6), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone-5-sodium sulfonate, and 2-cyano-3, 3-diphenylacrylate 2'-ethylhexyl acrylate. Preference is given to 4-aminobenzoic acid, N, N, N-trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline methylsulfate, 3,3,5-trimethylcyclohexyl salicylate, 2-hydroxy-4-methoxybenzophenone , 2-phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts, 3,3 '- (1,4-phenylenedimethylene) -bis (7,7-dimethyl-2-oxo-bicyclo- [2.2.1] hept-1-yl-methanesulfonic acid) and its salts, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) -propane-1,3-dione, α- (2-oxoborn-3-yl) yliden) -toluene-4-sulfonic acid and its salts, ethoxylated 4-aminobenzoic acid ethyl ester, 2-ethylhexyl 4-dimethylaminobenzoate, 2-ethylhexyl salicylate, isopentyl 4-methoxycinnamate, 2-ethylhexyl 4-methoxycinnamate, 2 Hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt, 3- (4'-methylbenzylidene) -D, L-camphor, 3-benzylidene-camphor, 4-isopropylbenzylsalicylate, 2,4,6-trianilino- (p-) carbo-2'-ethylhexyl-1'-oxi) -1,3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of N - {(2 and 4) - [2- oxoborn-3-ylidenemethyl] benzyl} acrylamide. Very particularly preferred according to the invention are 2-hydroxy-4-methoxybenzophenone, 2-phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) Propan-1,3-dione, 4-methoxycinnamic acid 2-ethylhexyl ester and 3- (4'-methylbenzylidene) -D, L-camphor.

Preference is given to those UV filters whose molar extinction coefficient at the absorption maximum is above 15,000, in particular above 20,000.

Furthermore, it has been found that structurally similar UV filters in many cases, the water-insoluble compound in the teaching of the invention has the higher effect compared to such water-soluble compounds that differ from it by one or more additional ionic groups. In the context of the invention, water-insoluble are to be understood as meaning those UV filters which dissolve in water at 20 ° C. to not more than 1% by weight, in particular not more than 0.1% by weight. Furthermore, these compounds should be soluble in the usual cosmetic oil components at room temperature to at least 0.1, in particular at least 1 wt .-%). The use of water-insoluble UV filters may therefore be preferred according to the invention.

According to a further embodiment of the invention, preference is given to those UV filters which have a cationic group, in particular a quaternary ammonium group.

These UV filters have the general structure U-Q.

• – substituierte Benzophenone,
• – p-Aminobenzoesäureester,
• – Diphenylacrylsäureester,
• – Zimtsäureester,
• – Salicylsäureester,
• – Benzimidazole und
• – o-Aminobenzoesäureester.

The structural part U stands for a UV-absorbing group. In principle, this group can be derived from the known UV filters which can be used in the cosmetics sector, in which a group, generally a hydrogen atom, of the UV filter is bound by a cationic group Q, in particular a quaternary amino function, is replaced. Compounds from which the structural part U can derive are, for example

• Substituted benzophenones,
• P-aminobenzoic acid ester,
• - diphenylacrylic acid ester,
• - cinnamic acid ester,
• Salicylic acid ester,
• Benzimidazoles and
• O-aminobenzoic acid ester.

Structural parts U which are derived from cinnamic acid amide or from N, N-dimethylaminobenzoic acid amide are preferred according to the invention.

The structural parts U can in principle be chosen such that the absorption maximum of the UV filters can be in both the UVA (315-400 nm) and in the UVB (280-315 nm) or in the UVC (<280 nm) range. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.

Furthermore, the structural part U, also as a function of structural part Q, is preferably selected so that the molar extinction coefficient of the UV filter at the absorption maximum is above 15,000, in particular above 20,000.

The structural part Q preferably contains, as a cationic group, a quaternary ammonium group. This quaternary ammonium group can in principle be connected directly to the structural part U, so that the structural part U represents one of the four substituents of the positively charged nitrogen atom. Preferably, however, one of the four substituents on the positively charged nitrogen atom is a group, especially an alkylene group of 2 to 6 carbon atoms, which functions as a compound between the structural portion U and the positively charged nitrogen atom.

Advantageously, the group Q has the general structure - (CH ₂ ) _X -N ⁺ R ¹ R ² R ³ X ^- , in which x is an integer from 1 to 4, R ¹ and R ² independently of one another are C _{1 -4} alkyl groups, R ³ is a C _1-22 alkyl group or a benzyl group and X ^{- is} a physiologically acceptable anion. In the context of this general structure, x preferably represents the number 3, R ¹ and R ² each represent a methyl group and R ^{3 represents} either a methyl group or a saturated or unsaturated, linear or branched hydrocarbon chain having 8 to 22, in particular 10 to 18, carbon atoms.

Physiologically acceptable anions are, for example, inorganic anions such as halides, in particular chloride, bromide and fluoride, sulfate ions and phosphate ions and organic anions such as lactate, citrate, acetate, tartrate, methosulfate and tosylate.

Two preferred UV filters with cationic groups are the commercially available compounds cinnamic acid trimethyl ammonium chloride (Incroquat ^® UV-283) and dodecyl tosylate (Escalol ^® HP 610).

Of course, the teaching of the invention also includes the use of a combination of several UV filters. In the context of this embodiment, the combination of at least one water-insoluble UV filter with at least one UV filter with a cationic group is preferred.

The UV filters (I) are usually contained in the agents according to the invention in amounts of 0.1-5% by weight, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.

The compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J). Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C ₁ - to C ₄ -alkyl groups. The sodium salt is most preferred. The amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total composition, particularly preferably from 0.1 to 5, and in particular from 0.1 to 3,% by weight.

Finally, the compositions according to the invention may also contain plant extracts (L). Usually these extracts are produced by extraction of the whole plant. However, in individual cases it may also be preferred to prepare the extracts exclusively from flowers and / or leaves of the plant.

With regard to the plant extracts which can be used according to the invention, particular reference is made to the extracts listed in the table beginning on page 44 of the 3rd edition of the guideline for the ingredient declaration of cosmetic products, published by the Industrial Association for Personal Care and Detergent e.V. (IKW), Frankfurt.

The extracts of green tea, oak bark, stinging nettle, witch hazel, hops, henna, chamomile, burdock root, horsetail, hawthorn, linden, almond, aloe vera, spruce needle, horse chestnut, sandalwood, juniper, coconut, mango, apricot, lime , Wheat, kiwi, melon, orange, grapefruit, sage, rosemary, birch, mallow, meadowfoam, quenelle, yarrow, thyme, lemon balm, toadstool, coltsfoot, marshmallow, meristem, ginseng and ginger root.

Particularly preferred are the extracts of green tea, oak bark, stinging nettle, witch hazel, hops, chamomile, burdock root, horsetail, lime blossom, almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi, melon, orange, grapefruit, sage, Rosemary, birch, meadowfoam, quenelle, yarrow, toadstool, meristem, ginseng and ginger root.

Especially suitable for the use according to the invention are the extracts of green tea, almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi and melon.

As extraction agent for the preparation of said plant extracts water, alcohols and mixtures thereof can be used. Among the alcohols are lower alcohols such as ethanol and isopropanol, but especially polyhydric alcohols such as ethylene glycol and propylene glycol, both as sole extractant and in admixture with water, are preferred. Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.

The plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2-80 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture.

Furthermore, it may be preferred to use in the compositions according to the invention mixtures of several, especially two, different plant extracts.

In addition, it may prove advantageous if the compositions according to the invention contain penetration aids and / or swelling agents (M). These include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol ethers, for example propylene glycol monoethyl ether, carbonates, bicarbonates, Diols and triols, and especially 1,2-diols and 1,3-diols such as 1,2-propanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-dodecanediol, 1,3-propanediol, 1 , 6-hexanediol, 1,5-pentanediol, 1,4-butanediol.

Advantageously in the context of the invention, short-chain carboxylic acids (N) may additionally support the active substance complex (A). Short-chain carboxylic acids and their derivatives in the context of the invention are understood to mean carboxylic acids which may be saturated or unsaturated and / or straight-chain or branched or cyclic and / or aromatic and / or heterocyclic and have a molecular weight of less than 750. For the purposes of the invention, preference may be given to saturated or unsaturated straight-chain or branched carboxylic acids having a chain length of from 1 to 16 C atoms in the chain, very particular preference being given to those having a chain length of from 1 to 12 C atoms in the chain.

The short-chain carboxylic acids according to the invention may have one, two, three or more carboxy groups. Preferred within the meaning of the invention are carboxylic acids having a plurality of carboxy groups, in particular di- and tricarboxylic acids. The carboxy groups may be wholly or partly present as esters, acid anhydride, lactone, amide, imidic acid, lactam, lactim, dicarboximide, carbohydrazide, hydrazone, hydroxam, hydroxime, amidine, amidoxime, nitrile, phosphonic or phosphate ester. The carboxylic acids used according to the invention may of course be substituted along the carbon chain or the ring skeleton. The substituents of the carboxylic acids used according to the invention include, for example, C 1 -C 8 -alkyl-, C 2 -C 8 alkenyl, aryl, aralkyl and aralkenyl, hydroxymethyl, C 2 -C 8 hydroxyalkyl, C 2 -C 8 hydroxyalkenyl, aminomethyl, C 2 -C 8 aminoalkyl, cyano, formyl, oxo , Thioxo, hydroxy, mercapto, amino, carboxy or imino groups. Preferred substituents are C 1 -C 8 alkyl, hydroxymethyl, hydroxy, amino and carboxy groups. Particularly preferred are substituents in position. Very particularly preferred substituents are hydroxy, alkoxy and amino groups, where the amino function may optionally be further substituted by alkyl, aryl, aralkyl and / or alkenyl radicals. Furthermore, preferred carboxylic acid derivatives are the phosphonic and phosphate esters.

A particularly preferred group of ingredients are the silicones.

• (i) Polyalkylsiloxanen, Polyarylsiloxanen, Polyalkylarylsiloxanen, die flüchtig oder nicht flüchtig, geradkettig, verzweigt oder cyclisch, vernetzt oder nicht vernetzt sind;
• (ii) Polysiloxanen, die in ihrer allgemeinen Struktur eine oder mehrere organofunktionelle Gruppen enthalten, die ausgewählt sind unter: a) substituierten oder unsubstituierten aminierten Gruppen; b) (per)fluorierten Gruppen; c) Thiolgruppen; d) Carboxylatgruppen; e) hydroxylierten Gruppen; f) alkoxylierten Gruppen; g) Acyloxyalkylgruppen; h) amphoteren Gruppen; i) Bisulfitgruppen; j) Hydroxyacylaminogruppen; k) Carboxygruppen; l) Sulfonsäuregruppen; und m) Sulfat- oder Thiosulfatgruppen;
• (iii) linearen Polysiloxan(A)-Polyoxyalkylen(B)-Blockcopoylmeren vom Typ (A-B)_n mit n > 3;
• (iv) gepfropften Siliconpolymeren mit nicht siliconhaltigem, organischen Grundgerüst, die aus einer organischen Hauptkette bestehen, welche aus organischen Monomeren gebildet wird, die kein Silicon enthalten, auf die in der Kette sowie gegebenenfalls an mindestens einem Kettenende mindestens ein Polysiloxanmakromer gepfropft wurde;
• (v) gepfropften Siliconpolymeren mit Polysiloxan-Grundgerüst, auf das nicht siliconhaltige, organische Monomere gepfropft wurden, die eine Polysiloxan-Hauptkette aufweisen, auf die in der Kette sowie gegebenenfalls an mindestens einem ihrer Enden mindestens ein organisches Makromer gepfropft wurde, das kein Silicon enthält;

oder deren Gemischen. Preferred agents according to the invention are characterized in that they comprise at least one silicone, preferably a silicone, selected from:

• (i) polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes which are volatile or nonvolatile, straight chain, branched or cyclic, crosslinked or uncrosslinked;
• (ii) polysiloxanes containing in their general structure one or more organofunctional groups selected from: a) substituted or unsubstituted aminated groups; b) (per) fluorinated groups; c) thiol groups; d) carboxylate groups; e) hydroxylated groups; f) alkoxylated groups; g) acyloxyalkyl groups; h) amphoteric groups; i) bisulfite groups; j) hydroxyacylamino groups; k) carboxy groups; l) sulfonic acid groups; and m) sulfate or thiosulfate groups;
• (iii) linear polysiloxane (A) polyoxyalkylene (B) block copolymers of the (AB) _{n type} with n>3;
• (iv) grafted silicone polymers having a non-silicone organic backbone consisting of an organic backbone formed from organic monomers containing no silicone grafted with at least one polysiloxane macromer in the chain and optionally at least one chain end;
• (v) grafted polysiloxane backbone silicone polymers having grafted thereto non-silicone organic monomers having a polysiloxane backbone to which at least one organic macromer not containing silicone has been grafted in the chain, and optionally at least at one of its ends ;

or their mixtures.

Particularly preferred compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.

Preferred silicones are described below.

Particularly preferred agents according to the invention are characterized in that they contain at least one silicone of the formula Si-I (CH ₃ ) ₃ Si- [O-Si (CH ₃ ) ₂ ] _x -O-Si (CH ₃ ) ₃ (Si-I), in which x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.

These silicones are called DIMETHICONE according to the INCI nomenclature. In the context of the present invention, as the silicone of the formula Si-1, the compounds are preferably:
(CH ₃ ) ₃ Si-O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si-O- (CH ₃ ) ₂ Si-O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₂ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₃ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₄ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₅ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₆ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₇ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₈ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₉ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₀ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₁ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₂ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₃ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₄ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₅ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₆ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₇ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₈ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₉ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₂₀ -O-Si (CH ₃ ) ₃
where (CH ₃ ) ₃ Si-O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si-O- (CH ₃ ) ₂ Si-O-Si (CH ₃ ) ₃ and / or (CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₂ -O-Si (CH ₃ ) _{3 are} particularly preferred.

Of course, mixtures of o.g. Silicones may be included in the compositions of the invention.

Preferred silicones which can be used according to the invention have viscosities of from 0.2 to 2 mm ² s ^-1 at 20 ° C., silicones having viscosities of from 0.5 to 1 mm ² s ^{-1 being} particularly preferred.

Particularly preferred agents according to the invention contain one or more amino-functional silicones. Such silicones may, for example, be represented by the formula M (R _a Q _b SiO _{(4-ab) / 2) x} (R _c SiO _{(4-c) / 2) y} M wherein R in the above formula is a hydrocarbon or a hydrocarbon group of 1 to about 6 carbon atoms, Q is a polar group of the general formula -R ¹ HZ wherein R ^{1 is} a divalent linking group attached to hydrogen and the group Z is an organic, amino-functional radical containing at least one amino-functional group, carbon and hydrogen atoms, carbon, hydrogen and oxygen atoms or carbon, hydrogen and nitrogen atoms; "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 1 to about 3, "a" + "b" is less than or equal to 3, and "c" is a number in the range from about 1 to about 3, and x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25, and y is a number ranging from about 20 to about 10,000 , preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000, and M is a suitable silicone end group as known in the art, preferably trimethylsiloxy. Non-limiting examples of the groups represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals such as cyclobutyl, cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, 4-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur containing radicals such as mercaptoethyl, mercaptopropyl, mercaptohexyl, mercaptophenyl and the like; preferably R is an alkyl radical containing from 1 to about 6 carbon atoms, and most preferably R is methyl. Examples of R ¹ include methylene, ethylene, propylene, hexamethylene, decamethylene, -CH ₂ CH (CH ₃ ) CH ₂ -, phenylene, naphthylene, -CH ₂ CH ₂ SCH ₂ CH ₂ -, -CH ₂ CH ₂ OCH ₂ - , -OCH ₂ CH ₂ -, -OCH ₂ CH ₂ CH ₂ -, -CH ₂ CH (CH ₃ ) C (O) OCH ₂ -, - (CH ₂ ) ₃ CC (O) OCH ₂ CH ₂ -, C ₆ H ₄ C ₆ H ₄ -, -C ₆ H ₄ CH ₂ C ₆ H ₄ -; and - (CH _{2) 3} C (O) SCH ₂ CH ₂ - one.

Z is an organic, amino-functional radical containing at least one functional amino group. A possible formula for Z is NH (CH ₂ ) _z NH ₂ , wherein z is 1 or more. Another possible formula for Z is -NH (CH ₂ ) _z (CH ₂ ) _zz NH, wherein both z and zz are independently 1 or more, which structure includes diamino ring structures, such as piperazinyl. Z is most preferably a -NHCH ₂ CH ₂ NH ₂ radical. Another possible formula for Z is -N (CH ₂ ) _z (CH ₂ ) _zz NX ₂ or -NX ₂ , wherein each X of X _{2 is} independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0.

Q is most preferably a polar, amine functional group of the formula -CH ₂ CH ₂ CH ₂ NHCH ₂ CH ₂ NH ₂ . In the formulas, "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 2 to about 3, "a" + "b" is less than or equal to 3, and "c "is a number in the range of about 1 to about 3. The molar ratio of the R _a Q _b SiO _{(4-ab) / 2} units to the R _c SiO _{(4-c) / 2} units is in the range of about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1:15 to about 1:20. When one or more silicones of the above formula are used, the various variable substituents in the above formula may be different for the various silicone components present in the silicone blend.

• – G ist–H, eine Phenylgruppe, -OH, -O-CH₃, -CH₃, -O-CH₂CH₃, -CH₂CH₃, -O-CH₂CH₂CH₃,-CH₂CH₂CH₃, -O-CH(CH₃)₂, -CH(CH₃)₂, -O-CH₂CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -O-CH₂CH(CH₃)₂, -CH₂CH(CH₃)₂, -O-CH(CH₃)CH₂CH₃, -CH(CH₃)CH₂CH₃, -O-C(CH₃)₃, -C(CH₃)₃;
• – a steht für eine Zahl zwischen 0 und 3, insbesondere 0;
• – b steht für eine Zahl zwischen 0 und 1, insbesondere 1,
• – m und n sind Zahlen, deren Summe (m + n) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei n vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt,
• – R´ ist ein monovalenter Rest ausgewählt aus – -Q-N(R")-CH₂-CH₂-N(R")₂ – -Q-N(R")₂ – -Q–N⁺(R")₃A^– – -Q–N⁺H(R")₂ A^– – -Q-N⁺H₂(R")A^– – -Q-N(R")-CH₂-CH₂-N⁺R"H₂A^–,

wobei jedes Q für eine chemische Bindung, -CH₂-, -CH₂-CH₂-, -CH₂CH₂CH₂-, -C(CH₃)₂-, -CH₂CH₂CH₂CH₂-, -CH₂C(CH₃)₂-, -CH(CH₃)CH₂CH₂- steht, R" für gleiche oder verschiedene Reste aus der Gruppe –H, -Phenyl, -Benzyl, -CH₂-CH(CH₃)Ph, der C_1-20-Alkylreste, vorzugsweise -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂H₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -C(CH₃)₃, steht und A ein Anion repräsentiert, welches vorzugsweise ausgewählt ist aus Chlorid, Bromid, Iodid oder Methosulfat. Preferred agents according to the invention are characterized in that they contain an amino-functional silicone of the formula (Si-II) R _'a G _3-a -Si (OSiG _{2) n} - (OSiG _b R' _{2-b) m} -O-SiG _3-a -R _'a (Si-II), contain, in which means:

• - G is -H, a phenyl group, -OH, -O-CH ₃ , -CH ₃ , -O-CH ₂ CH ₃ , -CH ₂ CH ₃ , -O-CH ₂ CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -O-CH (CH ₃ ) ₂ , -CH (CH ₃ ) ₂ , -O-CH ₂ CH ₂ CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₂ CH ₃ , -O-CH ₂ CH (CH ₃ ) ₂ , -CH ₂ CH (CH ₃ ) ₂ , -O-CH (CH ₃ ) CH ₂ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -OC (CH ₃ ) ₃ , -C (CH ₃ ) ₃ ;
• A is a number between 0 and 3, in particular 0;
• B is a number between 0 and 1, in particular 1,
• M and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n is preferably values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10,
• R 'is a monovalent radical selected from - -QN (R ") - CH ₂ -CH ₂ -N (R") ₂ - -QN (R ") ₂ - -Q-N ⁺ (R") ₃ A ^- - -Q-N ⁺ H (R ") ₂ A ^- - -QN ⁺ H ₂ (R") A ^- - -QN (R ") - CH ₂ -CH ₂ -N ⁺ R" H ₂ A ^- ,

wherein each Q is a chemical bond, -CH ₂ -, -CH ₂ -CH ₂ -, -CH ₂ CH ₂ CH ₂ -, -C (CH ₃ ) ₂ -, -CH ₂ CH ₂ CH ₂ CH ₂ -, -CH ₂ C (CH ₃ ) ₂ -, -CH (CH ₃ ) CH ₂ CH ₂ -, R "represents the same or different radicals from the group -H, -phenyl, -benzyl, -CH ₂ -CH (CH ₃ ) Ph, the C _1-20 -alkyl radicals, preferably -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH ₂ CH ₂ H ₃ , - CH ₂ CH (CH ₃ ) ₂ , -CH (CH ₃ ) CH ₂ CH ₃ , -C (CH ₃ ) ₃ , and A represents an anion, which is preferably selected from chloride, bromide, iodide or methosulfate.

enthalten, worin m und n Zahlen sind, deren Summe (m + n) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei n vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt. Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)

in which m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.

These silicones are referred to as trimethylsilylamodimethicones according to the INCI declaration.

enthalten, worin R für -OH, -O-CH₃ oder eine -CH₃-Gruppe steht und m, n1 und n2 Zahlen sind, deren Summe (m + n1 + n2) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei die Summe (n1 + n2) vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt. Also particularly preferred are agents according to the invention which are an amino-functional silicone of the formula (Si-IIb)

in which R is -OH, -O-CH ₃ or a -CH ₃ group and m, n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.

These silicones are referred to as amodimethicones according to the INCI declaration.

Regardless of which amino-functional silicones are employed, agents according to the invention which contain an amino-functional silicone whose amine number is above 0.25 meq / g, preferably above 0.3 meq / g and in particular above 0.4 meq / g, are preferred , The amine number stands for the milliequivalents of amine per gram of amino-functional silicone. It can be determined by titration and also expressed in mg KOH / g.

Agents preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.1 to 8% by weight, particularly preferably 0.25 to 7.5% by weight and in particular 0, 5 to 5 wt.% Amino-functional silicone (s) included.

enthalten, in der x für eine Zahl von 3 bis 200, vorzugsweise von 3 bis 10, weiter bevorzugt von30 bis 7 und insbesondere 3, 4, 5 oder 6, steht. The INCI CYCLOMETHICONE designated cyclic dimethicones are inventively used with preference. Here, agents according to the invention are preferred which contain at least one silicone of the formula Si-III

in which x is a number from 3 to 200, preferably from 3 to 10, more preferably from 30 to 7 and in particular 3, 4, 5 or 6.

The silicones described above have a backbone composed of -Si-O-Si units. Of course, these Si-O-Si units may also be interrupted by carbon chains. Appropriate molecules are accessible by chain extension reactions and are preferably used in the form of silicone-in-water emulsions.

Agents which are likewise preferred according to the invention are characterized in that they contain at least one silicone of the formula Si-IV R ₃ Si [O-SiR ₂ ] _x - (CH ₂ ) _n - [O-SiR ₂ ] _y -O-SiR ₃ (Si-IV), in which R is identical or different radicals from the group -H, -phenyl, -benzyl, -CH ₂ -CH (CH ₃ ) Ph, the C _1-20 -alkyl radicals, preferably -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH ₂ CH ₂ H ₃ , -CH ₂ CH (CH ₃ ) ₂ , -CH (CH ₃ ) CH ₂ CH ₃ , - C (CH ₃ ) ₃ , x and y are a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and especially 0, 1, 2, 3, 4, 5 or 6, stand and n is a number from 0 to 10, preferably from 1 to 8 and in particular from 2, 3, 4, 5, 6.

The silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone.

For aesthetic reasons, "clear" products are often preferred by consumers. Hair treatment compositions which are preferred according to the invention are therefore characterized in that they are transparent or translucent. In the context of the present invention, transparent or translucent is understood as meaning a composition which has an NTU value of less than 100. The Nephelometric Turbidity Unit (NTU) value is a unit used in water treatment for turbidity measurements in liquids. It is the unit of turbidity of a fluid measured with a calibrated nephelometer.

The compositions according to the invention have advantageous properties and also confer advantageous properties on the hair treated with them. In particular, in hair and scalp treatment benefits have been observed bvzw the advantages of the oligopeptides. Hyaluronic acid ester go out alone. Thus, hair treatment compositions according to the invention increase the elasticity of the hair treated with them and lead to an inner-structural strengthening of the hair fibers, which is reflected for example in higher melting temperatures in differential thermal analysis.

There is also an improvement in wet and dry combabilities and prevention of premature splitting in the treated hair. On the skin and in particular the scalp, the compositions according to the invention cause an increase in the elasticity and, surprisingly, sebum-regulating effects. The visual impression of "greasy" skin or hair is thus avoided or weakened.

• – Zugfestigkeit von keratinischen Fasern, insbesondere menschlichen Haaren;
• – Stabilisierung des Feuchtigkeitshaushaltes von keratinischen Fasern, insbesondere menschlichen Haaren;
• – Kämmbarkeit von keratinischen Fasern, insbesondere menschlichen Haaren;
• – Verzögerung des Alterungsprozesses von keratinischen Fasern, insbesondere menschlichen Haaren;
• – Restrukturierbarkeit von keratinischen Fasern, insbesondere menschlichen Haaren, während des und nach dem Dauerwellprozeß;
• – Verringerung der Elastizitätsabnahme von keratinischen Fasern, insbesondere menschlichen Haaren bei Beschädigung durch atmosphärische Einwirkungen bei dem ein Haarbehandlungsmittel, enthaltend – jeweils bezogen auf sein Gewicht –
• a) 0,0001 bis 10 Gew.-% mindestens eines Oligopetids, das mindestens eine Aminosäuresequenz Glu-Glu-Glu
  
  aufweist, wobei die Amino-Gruppe frei oder protoniert und die Carboxy-Gruppen frei oder deprotoniert vorliegen können,
• b) 0,0001 bis 10 Gew.-% mindestens einer Verbindung ausgewählt aus L-Carnitin, und/oder den Carnitinderivaten Acetyl-L-Carnitin, L-Carnitin-Fumarat, L-Carnitin-Citrat, Lauroyl- L-Carnitin und insbesondere L-Carnitin-Tartrat.

auf die keratinschen Fasern aufgetragen, dort 5 Sekunden bis 10 Minuten belassen und dann ausgespült wird. Another object of the present invention is a method for improving at least one of the properties

• Tensile strength of keratinic fibers, in particular human hair;
• Stabilization of the moisture balance of keratinic fibers, in particular human hair;
• Combability of keratinic fibers, in particular human hair;
• Delaying the aging process of keratinic fibers, in particular human hair;
• - Restrukturability of keratinic fibers, especially human hair, during and after the permanent wave process;
• Reduction of the elasticity decrease of keratinic fibers, in particular of human hair, when damaged by atmospheric effects in which a hair treatment composition containing - in each case based on its weight -
• a) 0.0001 to 10 wt .-% of at least one oligopeptide containing at least one amino acid sequence Glu-Glu-Glu
  
  wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated,
• b) 0.0001 to 10 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.

applied to the keratin fibers, left there for 5 seconds to 10 minutes and then rinsed out.

With respect to further preferred embodiments of the method according to the invention mutatis mutandis applies to the means of the invention.

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited patent literature

• WO 2010/026010 A1 [0004]
• EP 1539088 A1 [0005]
• WO 2008/028895 A1 [0005]
• EP 1996150 A1 [0005]
• FR 2971159 A1 [0006]
• EP 2588075 A1 [0006]
• DE 4413686 [0100]
• WO 92/13829 [0121]

Claims (10)

Hair treatment compositions containing - in each case based on its weight - a) 0.0001 to 10 wt .-% of at least one oligopeptide, the at least one amino acid sequence Glu-Glu-Glu

wherein the amino group is free or protonated and the carboxy groups are free or deprotonated b) 0.0001 to 10 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine , L-carnitine fumarate, L-carnitine citrate, lauroyl L-carnitine and especially L-carnitine tartrate. Hair treatment composition according to claim 1, characterized in that the oligopeptide comprises 5 to 15 amino acids, preferably 6 to 13 amino acids, more preferably 7 to 12 amino acids and especially 8, 9 or 10 amino acids and a molecular weight of 650 to 3000 Da, preferably 750 to 2500 Da, more preferably from 850 to 2000 Da and in particular from 1000 to 1600 Da. Hair treatment composition according to one of claims 1 or 2, characterized in that the oligopeptide Tyr-Glu-Glu-Glu-Ile

wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated. Hair treatment composition according to one of Claims 1 to 3, characterized in that the oligopeptide has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu

wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated. Hair treatment composition according to one of Claims 1 to 4, characterized in that it contains 0.0005 to 7.5% by weight, preferably 0.001 to 6% by weight, more preferably 0.005 to 5% by weight, more preferably 0.01 to 4 wt .-% and in particular 0.1 to 3 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl Contains L-carnitine and in particular L-carnitine tartrate. Hair treatment composition according to one of Claims 1 to 5, characterized in that it contains 0.0005 to 7.5% by weight, preferably 0.001 to 6% by weight, more preferably 0.005 to 5% by weight, more preferably 0.01 to 4 wt .-% and in particular 0.1 to 3 wt .-% purine and / or purine derivative (s) of the formula (I)

in which the radicals R ¹ , R ² and R ^{3 are} independently selected from -H, -OH, -NH ₂ , -SH and the radicals R ⁴ , R ⁵ and R ^{6 are} independently selected from -H, -CH ₃ and -CH ₂ -CH ₃ , where the following compounds are preferred: - purine (R ¹ = R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) - adenine (R ¹ = NH ₂ , R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) - guanine (R ¹ = OH, R ² = NH ² , R ³ = R ⁴ = R ⁵ = R ⁶ = H) - uric acid (R ¹ = R ² = R ³ = OH, R ⁴ = R ⁵ = R ⁶ = H) - hypoxanthine (R ¹ = OH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) - 6 purine thiol (R ¹ = SH , R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) - 6-thioguanine (R ¹ = SH, R ² = NH ² , R ³ = R ⁴ = R ⁵ = R ⁶ = H) - xanthine (R ¹ = R ² = OH, R ³ = R ⁴ = R ⁵ = R ⁶ = H) - caffeine (R ¹ = R ² = OH, R ³ = H, R ⁴ = R ⁵ = R ⁶ = CH ³ ) - theobromine (R ¹ = R ² = OH, R ³ = R ⁴ = H, R ⁵ = R ⁶ = H) - theophylline (R ¹ = R ² = OH, R ³ = H, R ⁴ = CH ₃ , R ⁵ = CH ₃ , R ⁶ = H). Hair treatment composition according to one of Claims 1 to 6, characterized in that it contains 0.0005 to 7.5% by weight, preferably 0.001 to 6% by weight, more preferably 0.005 to 5% by weight, more preferably 0.01 to 4 wt .-% and in particular 0.1 to 3 wt .-% of at least one extract of Pisum sativium. Hair treatment composition according to one of claims 1 to 7, characterized in that it contains, based on its weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight, more preferably from 2.5 to 35% by weight. and in particular from 5 to 25% by weight of anionic and / or nonionic and / or cationic and / or amphoteric surfactant (s). Hair treatment composition according to one of Claims 1 to 8, characterized in that it contains, based on its weight, from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight, more preferably from 0.2 to 3 , 5% by weight and in particular 0.25 to 2.5% by weight of cationic polymer (s), preferred cationic polymer (s) being / are selected from - poly (methacryloyloxyethyltrimethylammonium chloride) (INCI: Polyquaternium-37) and / or; Quaternized cellulose derivatives (INCI: Polyquaternium 10) and / or cationic alkylpolyglycosides and / or cationized honey and / or cationic guar derivatives and / or polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or or - copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acrylate and methacrylate and / or - vinylpyrrolidone-Vinylimidazoliummethochlorid copolymers and / or - quaternized polyvinyl alcohol and / or - Polyquaternium 2 and / or - Polyquaternium-7 and / or - Polyquaternium 17 and / or Polyquaternium 18 and / or Polyquaternium 24 and / or Polyquaternium 27. Process for improving at least one of the properties - tensile strength of keratinic fibers, in particular human hair; Stabilization of the moisture balance of keratinic fibers, in particular human hair; Combability of keratinic fibers, in particular human hair; Delaying the aging process of keratinic fibers, in particular human hair; - Restrukturability of keratinic fibers, especially human hair, during and after the permanent wave process; - Reduction of the elasticity of keratin fibers, in particular human hair when damaged by atmospheric agents, characterized in that a hair treatment composition containing - each based on its weight - a) 0.0001 to 10 wt .-% of at least one oligopeptide, the at least one amino acid sequence Glu-Glu-Glu

where the amino group is free or protonated and the carboxy groups can be free or deprotonated, b) 0.0001 to 10% by weight of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L- Carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and especially L-carnitine tartrate, applied to the keratin fibers, left there for 5 seconds to 10 minutes and then rinsed out.